Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders

ABSTRACT

A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. Ser. No. 14/478,175, filed Sep. 5, 2014, which claims priority under 35 U.S.C. § 119 to provisional applications U.S. Ser. No. 61/874,044 and U.S. Ser. No. 61/874,181, both filed Sep. 5, 2013, herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present disclosure generally relates to treatment of cancer, and, more specifically, to the inhibition of signaling molecules implicated in the invasion and metastasis of cancer cells.

BACKGROUND OF THE INVENTION

Metastasis or metastatic disease is the spread of a disease from one organ or part to another non-adjacent organ or part. Metastatic disease is primarily but not uniquely associated with malignant tumor cells and infections relating to cancer. (Klein, 2008, Science 321(5897):1785-88; Chiang & Massague, 2008, New Engl. J. Med. 359(26):2814-23).

Cancer occurs after a single cell in a tissue is genetically damaged in ways that result in the formation of a putative cancer stem cell possessing a malignant phenotype. These cancer stem cells are able to undergo uncontrolled abnormal mitosis, which serves to increase the total number of cancer cells at that location. When the area of cancer cells at the originating site become clinically detectable, it is called primary tumor. Some cancer cells also acquire the ability to penetrate and infiltrate surrounding normal tissues in the local area, forming a new tumor. The newly formed tumor in the adjacent site within the tissue is called a local metastasis.

Some cancer cells acquire the ability to penetrate the walls of lymphatic and/or blood vessels, after which they are able to circulate through the bloodstream (circulating tumor cells) to other sites and tissues in the body. This process is known (respectively) as lymphatic or hematogenous spread. After the tumor cells come to rest at another site, they re-penetrate through the vessel or walls (extravasion), continue to multiply, and eventually another clinically detectable tumor is formed. This new tumor is known as a metastatic (or secondary) tumor. Metastasis is one of the hallmarks of malignancy. Most tumors and other neoplasms can metastasize, although in varying degrees (e.g. basal cell carcinoma rarely metastasizes) (Kumar et al., 2005, “Robbins and Cotran Pathologic Basis of Disease”, 7th ed., Philadelphia: Elsevier Saunders).

Metastatic tumors are very common in the late stages of cancer. The most common places for the metastases to occur are the lungs, liver, brain, and the bones. There is also a propensity for a tumor to seed in particular organs. For example, prostate cancer usually metastasizes to the bones. In a similar manner, colon cancer has a tendency to metastasize to the liver. Stomach cancer often metastasizes to the ovaries in women. Breast tumor cells often metastasize to bone tissue. Studies have suggested that these tissue-selective metastasis processes are due to specific anatomic and mechanical routes.

Oncostatin M (OSM) is a 28 kDa multifunctional member of the IL-6 family of cytokines secreted by monocytes, macrophages, neutrophils and activated T-lymphocytes (Tanaka & Miyajima, Rev Physiol Biochem Pharmacol 149: 39-53, 2003). Proteolytic cleavage near the carboxy-terminus of the secreted OSM yields the fully active form of OSM, 209 amino acids length having two N-linked glycosylation sites. OSM belongs to the IL-6 family of cytokines that includes (IL-6, IL-11, leukemia inhibitory factor (LIF), cardiotrophin-1, ciliary neutotrophic factor (CNTF) and cardiotrophin-like cytokine (CLC)) which share a common receptor subunit, gp130 protein. In humans, OSM signals through receptor heterodimers consisting of gp130 and the LIFRα subunit or gp130 and the OSMRβ subunit. In contrast to the other cytokines of the IL-6 family, OSM binds gp130 directly and in the absence of any additional membrane-bound co-receptor (Gearing et al., Science 255: 1434-1437, 1992). Following OSM binding to gp130, OSMRβ or LIFRα are recruited to form a high-affinity signaling complex (Mosley et al., J Biol. Chem. 271: 32635-32643, 1996). Activation of either receptor results in signaling via the JAK/STAT pathway (Auguste et al., J Biol. Chem. 272: 15760-15764, 1997).

OSM is produced primarily by cells of immune system origin and, has been a target for diseases associated with autoimmune disorders.

It is an object of the present in invention to provide novel OSM antagonist pharmaceutical compositions and their use in preventing cancer metastasis.

SUMMARY OF THE INVENTION

To achieve these and other advantages, and in accordance with the purposes of the present invention, as embodied and broadly described herein, the present invention relates to a method of reducing tumor cell detachment, proliferation and/or metastasis involving administering at least one OSM antagonist or OSM receptor antagonist to a subject. In a preferred embodiment the tumor cells are those associated with prostate or breast cancer.

Any number of OSM or OSM receptor antagonists may be employed, alone, or in combination with other therapies for treating or reducing metastasis and tumor cell migration. OSM antagonists may include small molecules, antibodies, antibody-derived reagents, or chimeric molecules. Included in the definition of antagonist is a structural or functional mimetic of any such molecule described above. Also contemplated are nucleic acid molecules such as DNA or RNA aptamers.

The antagonist may function by blocking OSM from interaction with the OSM receptor gp130, or the other OSM receptors, OSMrβ chain or LIFr, or by blocking formation of heterodimers of these proteins, and as such prevent OSM binding and signaling thereby reducing synthesis of cytokines and/or matrix metalloproteinases (MMPs). The antagonist according to the invention may therefore be a ligand for either OSM or one or more of the OSM receptors (gp130, OSMrβ or LIFr) or an agent capable of interfering with these interactions in a manner which affects OSM biological activity. Hereinafter reference to an antagonist to OSM can be taken to mean either an antagonist to OSM itself or to one of its receptors.

Administration of at least one OSM or OSM receptor antagonist, alone, or in combination with one or more therapies can be administered to a patient in need thereof to reduce tumor cell detachment, proliferation and/or metastasis.

One embodiment provides a pharmaceutical composition including an OSM antagonist in an amount effective to inhibit or reduce tumor cell detachment, proliferation and/or metastasis.

Another embodiment provides methods for inhibiting tumor cell detachment, proliferation and/or metastasis by administering an OSM antagonist. Preferably, the OSM antagonist specifically binds to OSM or the OSM receptor and inhibits or reduces OSM biological activity.

Another embodiment provides methods for identifying inhibitors of OSM.

BRIEF DESCRIPTION OF THE DRAWINGS

The following figures are included to illustrate certain aspects of the present disclosure, and should not be viewed as exclusive embodiments. The subject matter disclosed is capable of considerable modifications, alterations, combinations, and equivalents in form and function, as will occur to those skilled in the art and having the benefit of this disclosure.

FIG. 1A. OSM is present at high levels in tissues with ductal carcinoma in situ and invasive ductal carcinoma, as compared to adjacent normal breast and metastatic tissues by immunohistochemistry. Human breast tissue (adjacent normal, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC)) were stained with 1:400 dilution of hOSM antibody. Secondary antibody (rabbit anti-goat) alone served as a negative control. OSM is visualized by red-brown staining. Images were taken using 100× and 400× magnification with a light microscope. FIG. 1B OSM is highly expressed in the primary mammary tumor, and recruited cells of the lung microenvironment. Histology using H&E confirms the presence of a large, primary mammary tumor (T) 32 days after tumor cell injection into the 4^(th) mammary fat pad of female Balb/c mice and high OSM expression in the tumor as well as background expression in the normal breast connective tissue (CT). OSM expression is shown to be highest in the invasive edge of the tumor (T) closest to the normal breast connective tissue (CT). Control slides with no primary OSM antibody show low background staining.

FIGS. 2A-2B. The number of metastases was reduced by more than 50% in mice injected with 4T1.2-shOSM2 cells compared to control 4T1.2-LacZ control cells at both mid and late stages of metastasis. FIG. 2B shows histology slides.

FIGS. 3A-3C. Reduced OSM expression results in fewer spontaneous lung metastases and lower total volume of lung metastases by MRI. FIG. 3A, spontaneous lung metastases are more frequently detected by MRI beginning at day 20-21 until the endpoint of the experiment 29-30 of mice orthotopically injected with parental 4T1.2 or control 4T1.2-LacZ cells as compared to 4T1.2-shOSM2 cells. FIG. 3B, quantification of the total number and FIG. 3C, volume of lung metastases shows significantly higher lung metastases in the 4T1.2 or 4T1.2-LacZ injected mice as compared to the 4T1.2-shOSM2 injected mice. (4T1.2, n=6; 4T1.2-LacZ, n=7; 4T1.2-shOSM2, n=7). Data expressed as mean±SEM, *P<0.05, **P<0.01, t-test.

FIGS. 4A-4C. Reduced OSM expression by 4T1.2 tumors increases survival. FIG. 4A, the timeline shows orthotopic mammary tumor cell injection at day 0, resection at day 14, and final day of sacrifice per group. Kaplan-Meier analysis of survival following tumor resection shows a significant increase in survival in mice injected with 4T1.2-shOSM1 cells and 4T1.2-shOSM2 cells as compared to control 4T1.2-LacZ cells. FIG. 4B, the timeline shows intracardiac mammary tumor cells injection at day 0 and final day of sacrifice. Kaplan-Meier analysis of survival shows no difference in survival in mice injected with control 4T1.2-LacZ and 4T1.2-shOSM2 cells and FIG. 4C, also no difference in the amount of lung metastases quantified by qPCR. (4T1.2-LacZ, n=8-9; 4T1.2-shOSM1, n=7; 4T1.2-shOSM2, n=9-12) Data expressed as mean±SEM. *P<0.05, ***P<0.001, Log-rank test.

FIGS. 5A and 5B show plots of decreased detached 4T1.2 mammary tumor cells and 4T1.2 cell migration with OSM treatment (25 ng/ml).

FIGS. 6A-6F show human MDA-MB-231 D3H2LN cells in vivo. FIG. 6A. The timeline shows orthotopic mammary tumor cell injection at day 0, peri-tumoral OSM or PBS injections beginning 3× per week at day 13, and final day of sacrifice of both groups at day 61. FIG. 6B. MDA-MB-231 D3H2LN luc2 cells were injected into the fourth mammary fat pad of female nude mice and tumor growth was measured using calipers. Average tumor volume (mm³) did not differ between the peri-tumorally injected OSM and PBS control groups. FIGS. 6C and 6D. Representative images of PBS and OSM injected tumor-bearing mice imaged ventrally by BLI. Tumors with high BLI produced background on adjacent mice. This background is labeled with *. Ex vivo lungs from mice bearing MDA-MB-231 D3H2LN luc2 tumors injected peri-tumorally with PBS or OSM. Note the difference in BLI intensity between the groups. Bioluminescence intensities were quantified ex vivo in the lung. Lungs from mice receiving peri-tumoral OSM injections showed a 200 fold higher BLI intensity as compared to PBS injections. Data expressed as photon/s (mean±SEM; n=5-6), and expressed graphically is shown in FIGS. 6E and 6F.

FIG. 7 shows a plot of increased IL-6 expression in the presence of OSM. IL-6 levels were measured by ELISA on conditioned media from various OSM treated cells. ER negative MDA-MB-231, MDA-MB468, and 4T1.2 cells displayed high levels of induction (4-5 fold), while IL-6 levels did not change in the ER positive cell lines T47D and MCF7.

FIG. 8 shows a schematic comparing orthotopic and intracardiac injection. OSM's prometastatic effects occur early in the metastatic cascade. OSM increases detachment, EMT, angiogenesis through VEGF and HIF1a, invasion, proteases, and may subsequently increase intravasation into the blood vessels. OSM does not have any effect on extravasation and colonization at a secondary site.

FIGS. 9A and 9B show a plot of demonstrating how OSM promotes metastases to the lung and other organs in a 4T1.2 orthotopic mouse model.

FIG. 10 shows a schematic of the mechanism by which OSM is presumed to promote the metastasis and progression of prostate tumors.

FIGS. 11A and 11B show proliferation for Du145 and PC3 prostate cancer cell lines. FIG. 11A. The prostate cancer cell line Du-145 shows increased proliferation after 5 days of treatment with OSM (17.5 ng/ml) compared to untreated cells. FIG. 11B. The prostate cancer cell line PC-3 did not show increased proliferation in response to OSM treatment (17.5 ng/ml).

FIGS. 12A and 12B show detachment Changes for the DU-145 and PC-3 Prostate Cancer Cell Lines. FIG. 12A. The prostate cancer cell line Du-145 shows increased detachment after 5 days of treatment with OSM (17.5 ng/ml) compared to untreated cells. FIG. 12B. The prostate cancer cell line PC-3 did not show increased detachment in response to OSM treatment (17.5 ng/ml).

FIG. 13. Morphology changes for DU-145 prostate cancer cell line. After 5 days of OSM treatment (17.5 ng/ml), DU-145 cells exhibit a mesenchymal orphology characteristic of having undergone EMT. Untreated prostate cancer cells exhibit a more epithelial morphology and form more tightly packed colonies.

FIG. 14. Invasive Potential for the DU-145 and PC-3 Prostate Cancer Cell Lines. Both the DU-145 and PC-3 cell lines show an increased invasion potential as demonstrated by Matrigel assays after 24 hours of OSM treatment (17.5 ng/ml).

FIGS. 15A and 15B. OSM-SMI-8 decreases OSM-induced detachment in human prostate cancer cells. Detachment for FIG. 15A) Du145 and 15B) PC3+STAT3 human prostate cancer cells. 10,000 cells were plated in a 24-well plate in 1 mL complete media that was pre-incubated with OSM (5 ng/mL) and inhibitors (5 μM) for 1 hour. After 5 days, the detached cells were stained with Trypan Blue and counted using a hemocytometer. OSM-SMI-1 does not decrease detachment, while OSM-SMI-8, -10, and -11 decrease OSM-induced detachment.

FIGS. 16A-16D. OS-induced pSTAT3 is blocked by OSM-SMI-8. FIG. 16A, human breast cancer cells treated with OSM (25 ng/ml) induce pSTAT3 expression as measured by ELISA. Neutralizing antibodies to OSM or gp130 attenuate pSTAT3 levels. This method can be used for in vitro screening of lead compounds that inhibit OSM signaling. (mean±SEM; n=3; p<0.001 between +OSM versus either anti-OSM or anti-gp130, unpaired t-test) FIG. 16B, T47D human breast cancer cells, FIG. 16C, MDA-MB-231 human breast cancer cells, and FIG. 16D, Du145 human prostate cancer cells were pre-treated with OSM-SMI-1 to -16 (Table 1; 5 μM) for 2 hours and then treated with OSM (5 ng/ml) for 30 minutes. Cell lysates were collected and pSTAT3 levels were measure by ELISA. OSM-SMI-8 inhibition of pSTAT3 suggests decreased OSM signaling.

FIGS. 17A and 17B show OSM-SMI-8 inhibits OSM signaling in human MDA-MB-231 cells. FIG. 17A, an IC₅₀ concentration of 531 μM was determined for MDA-MB-231 cells blocked with OSM-SMI-8 (and then treated with OSM (5 ng/ml) for 30 minutes. FIG. 17B, three OSM-SMIs were assessed in two independent sets of MDA-MB-231 cell lysates by Western blot analysis for suppression of downstream pSTAT3, pJNK, pERK, and pAKT signaling. STAT3 and actin protein levels were used as internal loading controls.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure generally relates to treatment of cancer, and, more specifically, to the inhibition of signaling molecules implicated in the invasion and metastasis of cancer.

Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the present specification and associated claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification are approximations that may vary depending upon the desired properties sought to be obtained by the present embodiments. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claim, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

One or more illustrative embodiments incorporating the features disclosed herein are presented below. Not all features of a physical implementation are necessarily described or shown in this application for the sake of clarity. It is to be understood that in the development of a physical embodiment incorporating the embodiments of the present disclosure, numerous implementation-specific decisions can be made to achieve the developer's goals, such as compliance with system-related, business-related, government-related and other constraints, which vary by implementation and from time to time. While a developer's efforts might be time-consuming, such efforts would be, nevertheless, a routine undertaking for those of ordinary skill the art and having benefit of this disclosure.

While compositions and methods are described herein in terms of “comprising” various components or steps, the compositions and methods can also “consist essentially of” or “consist of” the various components and steps.

As used herein, the term “prevent” or “prevention” means no disorder or disease development if none had occurred, or no further disorder or disease development if there had already been development of the disorder or disease. Also considered is the ability of one to prevent some or all of the symptoms associated with the disorder or disease. Disease and disorder are used interchangeably herein.

The terms “inhibit” and “antagonize”, as used herein, mean to reduce a molecule, a reaction, an interaction, a gene, an mRNA, and/or a protein's expression, stability, function or activity by a measurable amount or to prevent entirely. Inhibitors are compounds that, e.g., bind to, partially or totally block stimulation, decrease, prevent, delay activation, inactivate, desensitize, or down regulate a protein, a gene, and an mRNA stability, expression, function and activity, e.g., antagonists.

As used herein, the terms “effective amount” or “therapeutically effective amount” or “pharmaceutically effective amount” of a compound are used interchangeably to refer to the amount of the compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered. The term to “treat,” as used herein, means reducing the frequency with which symptoms are experienced by a patient or subject or administering an agent or compound to reduce the severity with which symptoms are experienced. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. By the term “specifically bind” or “specifically binds,” as used herein, is meant that a first molecule (e.g., an antibody) preferentially binds to a second molecule (e.g., a particular antigenic epitope), but does not necessarily bind only to that second molecule.

As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

As used herein, the term “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to: intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.

The language “pharmaceutically acceptable carrier” includes a pharmaceutically acceptable salt, pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a compound(s) of the present invention within or to the subject such that it may perform its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each salt or carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, and not injurious to the subject. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; diluent; granulating agent; lubricant; binder; disintegrating agent; wetting agent; emulsifier; coloring agent; release agent; coating agent; sweetening agent; flavoring agent; perfuming agent; preservative; antioxidant; plasticizer; gelling agent; thickener; hardener; setting agent; suspending agent; surfactant; humectant; carrier; stabilizer; and other non-toxic compatible substances employed in pharmaceutical formulations, or any combination thereof. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound, and are physiologically acceptable to the subject. Supplementary active compounds may also be incorporated into the compositions.

As used herein, the term “antagonist” generally refers to the property of a molecule, compound or other agent to, for example, interfere with the binding of one molecule with another molecule or the stimulation of one cell by another cell either through steric hindrance, conformational alterations or other biochemical mechanisms. In one regard, the term antagonist relates to the property of an agent to prevent the binding of a receptor to its ligand, e.g., the binding of OSM with gp 130 or other OSM receptors, thereby inhibiting the signal transduction pathway triggered by OSM. The term antagonist is not limited by any specific action mechanism, but, rather, refers generally to the functional property presently defined. Antagonists of the present invention include, but are not limited to: small molecules and chemical compounds that bind to OSM or one of its receptors as well as OSM antibodies and fragments, muteins, and modifications thereof, peptides, and nucleic acid molecules such as antisense or RNAi compounds that inhibit expression of OSM.

As used herein, the term “heavy chain antibody” or “heavy chain antibodies” comprises immunoglobulin molecules derived from camelid species, either by immunization with an antigen and subsequent isolation of sera, or by the cloning and expression of nucleic acid sequences encoding such antibodies. The term “heavy chain antibody” or “heavy chain antibodies” further encompasses immunoglobulin molecules isolated from an animal with heavy chain disease, or prepared by the cloning and expression of V_(H) (variable heavy chain immunoglobulin) genes from an animal.

By the term “synthetic antibody” as used herein, is meant an antibody which is generated using recombinant DNA technology, such as, for example, an antibody expressed by a bacteriophage as described herein. The term should also be construed to mean an antibody which has been generated by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein, or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using synthetic DNA or amino acid sequence technology which is available and well known in the art.

The term “antigen” or “Ag” as used herein is defined as a molecule that provokes an immune response. This immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. A skilled artisan will understand that any DNA, which comprises a nucleotide sequences or a partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an “antigen” as that term is used herein. Furthermore, one skilled in the art will understand that an antigen need not be encoded solely by a full length nucleotide sequence of a gene. It is readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to elicit the desired immune response. Moreover, a skilled artisan will understand that an antigen need not be encoded by a “gene” at all. It is readily apparent that an antigen can be generated synthesized or can be derived from a biological sample. Such a biological sample can include, but is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.

By the term “applicator,” as the term is used herein, is meant any device including, but not limited to, a hypodermic syringe, a pipette, and the like, for administering the compounds and compositions of the invention.

As used herein, “aptamer” refers to a small molecule that can bind specifically to another molecule. Aptamers are typically either polynucleotide- or peptide-based molecules. A polynucleotidal aptamer is a DNA or RNA molecule, usually comprising several strands of nucleic acids, that adopt highly specific three-dimensional conformation designed to have appropriate binding affinities and specificities towards specific target molecules, such as peptides, proteins, drugs, vitamins, among other organic and inorganic molecules. Such polynucleotidal aptamers can be selected from a vast population of random sequences through the use of systematic evolution of ligands by exponential enrichment. A peptide aptamer is typically a loop of about 10 to about 20 amino acids attached to a protein scaffold that bind to specific ligands. Peptide aptamers may be identified and isolated from combinatorial libraries, using methods such as the yeast two-hybrid system.

“Naturally-occurring” as applied to an object refers to the fact that the object can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism (including viruses) that can be isolated from a source in nature and which has not been intentionally modified by man is a naturally-occurring sequence.

As used herein “endogenous” refers to any material from or produced inside an organism, cell, tissue or system.

As used herein, the term “exogenous” refers to any material introduced from or produced outside an organism, cell, tissue or system.

The term “epitope” as used herein is defined as a small chemical molecule on an antigen that can elicit an immune response, inducing B and/or T cell responses. An antigen can have one or more epitopes. Most antigens have many epitopes; i.e., they are multivalent. In general, an epitope is roughly five amino acids and/or sugars in size. One skilled in the art understands that generally the overall three-dimensional structure, rather than the specific linear sequence of the molecule, is the main criterion of antigenic specificity and therefore distinguishes one epitope from another.

“Polypeptide” refers to a polymer composed of amino acid residues, related naturally occurring structural variants, and synthetic non-naturally occurring analogs thereof linked via peptide bonds. Synthetic polypeptides can be synthesized, for example, using an automated polypeptide synthesizer.

The term “protein” typically refers to large polypeptides. The term “peptide” typically refers to short polypeptides. Conventional notation is used herein to portray polypeptide sequences: the left-hand end of a polypeptide sequence is the amino-terminus; the right-hand end of a polypeptide sequence is the carboxyl-terminus.

As used herein, a “peptidomimetic” is a compound containing non-peptidic structural elements that is capable of mimicking the biological action of a parent peptide. A peptidomimetic may or may not comprise peptide bonds.

“Instructional material,” as that term is used herein, includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition and/or compound of the invention in a kit. The instructional material of the kit may, for example, be affixed to a container that contains the compound and/or composition of the invention or be shipped together with a container which contains the compound and/or composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the recipient uses the instructional material and the compound cooperatively. Delivery of the instructional material may be, for example, by physical delivery of the publication or other medium of expression communicating the usefulness of the kit, or may alternatively be achieved by electronic transmission, for example by means of a computer, such as by electronic mail, or download from a website.

Throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.

I). OSM Antagonists

The antagonist may function by blocking OSM from interaction with the OSM receptor gp130, or the other OSM receptors, OSMrβ chain or LIFr, or by blocking formation of heterodimers of these proteins, and as such prevent OSM binding and signaling thereby reducing synthesis of cytokines and/or MMPs. The antagonist according to the invention may therefore be a ligand for either OSM or one or more of the OSM receptors (gp130, OSMrβ or LIFr) or an agent capable of interfering with these interactions in a manner which affects OSM biological activity. Hereinafter reference to an antagonist to OSM can be taken to mean either an antagonist to OSM itself or to one of its receptors.

Nucleic acid and amino acid sequences are known and generally available to those of skill in the art at places such as Gen bank, Swiss Prot, and EMBL. They are also disclosed herein as SEQ ID NOS:1 and 2. Further, amino acid residues which are important for OSM's interaction with gp130 have been identified. From the published amino acid sequence of OSM (Malik et al., 1989, Mol. Cell. Biol., 9(7), 2847-53, DNA sequence entry M27288 in EMBL database, protein sequence entry P13725 in Swissprot) these are G120, Q16 and Q20; N123 and N124 may also play a part. The first 25 residues are a signal peptide, and the mature protein begins at the sequence AAIGS. The sequence is numbered from the first amino acid of the mature protein as shown ion SEQ ID NO: 1.

The invention therefore further provides an antagonist or agent capable of interacting with one or more of these specific residues and/or the binding sites they help to define on OSM to alter OSM biological activity.

Potential antagonists of OSM include small organic molecules, ions which interact specifically with OSM for example a substrate possibly a natural substrate, a cell membrane component, a receptor or a natural ligand, a fragment thereof or a peptide or other proteinaceous molecule, particularly preferred is a non-signaling mutant form of OSM which will block binding of OSM to the OSM receptor, but also modified OSM molecules. Such antagonists may be in the form of DNA encoding the protein or peptide and may be delivered for in vivo expression of said antagonist. Antagonists may be vaccines comprising such protein or peptide molecules or DNA, designed to produce an antagonistic effect towards OSM via induction of antibody responses in vivo targeted towards native OSM. Such antagonists may also include antibodies, antibody-derived reagents or chimeric molecules. Included in the definition of antagonist is a structural or functional mimetic of any such molecule described above. Also contemplated are nucleic acid molecules such as DNA or RNA aptamers.

OSM antagonists of the present invention include, where applicable, functional equivalents. For example, molecules may differ in length, structure, components, etc., but may still retain one or more of the defined functions. Preferred OSM antagonist small molecules may be modified to include side groups, or other chemical additions which do not affect the antagonist activity.

Further, functional equivalents of the antibodies, antibody fragments or peptides of the present invention may include mimetic compounds, i.e., constructs designed to mimic the proper configuration and/or orientation for antigen binding.

OSM antagonists may optionally be modified by addition of side groups, etc., e.g., by amino terminal acylation, carboxy terminal amidation or by coupling of additional groups to amino acid side chains. Antagonists may also comprise one or more conservative amino acid substitutions. By “conservative amino acid substitutions” is meant those changes in amino acid sequence that preserve the general charge, hydrophobicity/hydrophilicity and/or steric bulk of the amino acid substituted. For example, substitutions between the following groups are conservative: Gly/Ala, Val/Ile/Leu, Asp/Glu, Lys/Arg, Asn/Gln, Ser/Cys/Thr, and Phe/Trp/Tyr. Such modifications will not substantially diminish the efficacy of the OSM antagonists and may impart such desired properties as, for example, increased in vivo half-life or decreased toxicity.

The invention is also intended to include polypeptides bearing modifications other than the insertion, deletion, or substitution of amino acid residues. By way of example, the modifications may be covalent in nature, and include for example, chemical bonding with polymers, lipids, other organic, and inorganic moieties. Such derivatives may be prepared to increase circulating half-life of a polypeptide, or may be designed to improve targeting capacity for the polypeptide to desired cells, tissues, or organs. Similarly, the invention further embraces OSM or OSMR polypeptides that have been covalently modified to include one or more water soluble polymer attachments such as polyethylene glycol, polyoxyethylene glycol, or polypropylene glycol.

A. OSM Small Molecules

Preferred antagonists include small organic molecules. Such compounds may be from any class of compound but will be selected on the basis of their ability to affect the biological activity of OSM through one of the mechanisms described above and will be physiologically acceptable (non-toxic or demonstrating an acceptable level of toxicity or other side-effects). One class of compounds which may provide useful antagonists are ribonucleosides such as N-(1H-pyrazolo[3,4-d]pyrimidin-4-yl) benzamide); Davoll and Kerridge, J. Chem Soc., 2589, 1961). According to the invention, OSM small molecule antagonists include those listed herein in Table 1 and Table 2. Any stereochemistry depicted in the formula's in Tables 1 and 2 is intended to be informative only and non-limiting. Any compound with the same basic chemical formula is intended to be included as are derivatives, isomers, and modifications.

TABLE 1 AutoDock Predicted Binding OSM Free Binding Energy Constant Chemical Class Structure Compound ID (kcal/mol) (uM) bis(benzimidazole) (1)

NCI 61610 −9.33 0.14 spirocyclopropane (2)

CB_CL 181230 −8.56 0.53 spirocyclopropane (3)

CB_CL 81250 −8.39 0.71 spirocyclopropane (4)

CB_CL 111696 −8.54 0.55 quinolone (5)

Florida ZINC 15777366 −8.27 0.87 spirocyclopropane (6)

CB_CL 19531 −8.44 0.65 dihydronaphthalene- 2-one (7)

Florida ZINC 15770835 −7.47 3.35 benzochromene (8)

Florida ZINC 32603276 −7.53 3.02 naphthyridine-2-one (9)

CB_CL 12813 −7.30 4.46 phenanthridine-6- one (10)

NCI 127133 −7.12 6.04

TABLE 2 AutoDock Predicted Binding Binding Compound Compound Free Energy Constant Number ID (kcal/mol) (uM) OSM-SMI-1  NSC21357

−6.88 9.11 OSM-SMI-2  NSC81514

−6.04 27.52 OSM-SMI-3  NSC105360

−8.45 0.64 OSM-SMI-4  NSC112821

−5.81 55.05 OSM-SMI-5  NSC348965

−7.93 1.53 OSM-SMI-6  NSC382916

−8.99 0.26 OSM-SMI-7  NSC636120

−8.26 0.88 OSM-SMI-8  NSC642624

−7.56 2.87 OSM-SMI-9  NSC645072

−7.03 7.05 OSM-SMI-10 NSC647257

−9.86 0.06 OSM-SMI-11 NSC648596

−5.87 50.04 OSM-SMI-12 NSC127133

−7.12 6.04 OSM-SMI-13 NSC61610

−9.33 0.14 OSM-SMI-14 CB_CL111696

−8.54 0.55 OSM-SMI-15 CB_CL19531

−8.44 0.65 OSMI-SMI-16 CB_CL81250

−8.39 0.71 NSC: National Cancer Institute Diversity Set III, CB_CL: ChemBridge Combinational Libraries

B. OSM Antibodies

The term “antibody” is used in the broadest-sense and includes fully assembled antibodies, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments that can bind antigen (e.g., Fab′, F′(ab)2, Fv, single chain antibodies, diabodies), and recombinant peptides comprising the forgoing as long as they exhibit the desired biological activity.

The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that are typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the homogeneous culture, uncontaminated by other immunoglobulins with different specificities and characteristics.

The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature, 256:495 [1975], or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624628[1991] end Marks et al., J. Mol. Biol., 222.1581-597 (1991), for example.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes, IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses or isotypes, e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy-chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma- and mu respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. Different isotypes have different effector functions; for example, IgG1 and IgG3 isotypes have ADCC activity.

In certain embodiments, the monoclonal, human, humanized, Human Engineered™ or variant anti-OSM antibody is an antibody fragment, such as an RX1, 5H4, MC1, or MC3 antibody fragment. Various techniques have been developed for the production of antibody fragments. Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985)). However, these fragments can now be produced directly by recombinant host cells. Better et al., Science 240: 1041-1043 (1988) disclose secretion of functional antibody fragments from bacteria (see, e.g., Better et al., Skerra et al., Science 240: 1038-1041 (1988)). For example, Fab′-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab′)2 fragments (Carter et al., Bio/Technology 10:163-167 (1992)). In another embodiment, the F(ab′)2 is formed using the leucine zipper GCN4 to promote assembly of the F(ab′)2 molecule. According to another approach, Fv, Fab or F(ab′)2 fragments can be isolated directly from recombinant host cell culture. Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.

An “isolated” antibody is one that has been identified and separated and for recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

For a detailed description of the structure and generation of antibodies, see Roth, D. B., and Craig, N. L., Cell, 94:411-414 (1998), and U.S. Pat. No. 6,255,458, herein incorporated by reference in its entirety. Briefly, the process for generating DNA encoding the heavy and light chain immunoglobulin genes occurs primarily in developing B-cells. Prior to the rearranging and joining of various immunoglobulin gene segments, the V, D, J and constant (C) gene segments are found generally in relatively close proximity on a single chromosome. During B-cell-differentiation, one of each of the appropriate family members of the V, D, J (or only V and J in the case of light chain genes) gene segments are recombined to form functionally rearranged heavy and light immunoglobulin genes. This gene segment rearrangement process appears to be sequential. First, heavy chain D-to-J joints are made, followed by heavy chain V-to-DJ joints and light chain V-to-J joints.

As provided herein, the compositions for and methods of treating or preventing tumor cell detachment, proliferation and/or metastasis may utilize one or more antibody used singularly or in combination with other therapeutics to achieve the desired effects. Antibodies according to the present invention may be isolated from an animal producing the antibody as a result of either direct contact with an environmental antigen or immunization with the antigen. Alternatively, antibodies may be produced by recombinant DNA methodology using one of the antibody expression systems well known in the art (See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1988)). Such antibodies may include recombinant IGs, chimeric fusion-proteins having immunoglobulin derived sequences or “Human Engineered” antibodies that may all be used for the treatment and prevention of tumor cell detachment, proliferation and/or metastasis according to the present invention. In addition to intact, full-length molecules, the term “antibody” also refers to fragments thereof (such as, e.g., scFv, Fv, Fd, Fab, Fab′ and F(ab)′2 fragments) or multimers or aggregates of intact molecules and/or fragments that bind to OSM (or OSMR). These antibody fragments bind antigen and may be derivatized to exhibit structural features that facilitate clearance and uptake, e.g., by incorporation of galactose residues.

In one embodiment of the present invention, OSM monoclonal antibodies may be prepared essentially as described in Halenbeck et al. U.S. Pat. No. 5,491,065 (1997), incorporated herein by reference. Exemplary OSM monoclonal antibodies include those that bind to an apparent conformational epitope associated with recombinant or native dimeric OSM with concomitant neutralization of biological activity. These antibodies are substantially unreactive with biologically inactive forms of OSM including monomeric and chemically derivatized dimeric OSM.

In other embodiments of the present invention, Human Engineered anti-OSM monoclonal antibodies are provided. The phrase “Human Engineered antibody” refers to an antibody derived from a non-human antibody, typically a mouse monoclonal antibody. Alternatively, a Human Engineered antibody may be derived from a chimeric antibody that retains or substantially retains the antigen binding properties of the parental, non-human, antibody but which exhibits diminished immunogenicity as compared to the parental antibody when administered to humans. The phrase “chimeric antibody,” as used herein, refers to an antibody containing sequence derived from two different antibodies (see, e.g., U.S. Pat. No. 4,816,567) which typically originate from different species. Most typically, chimeric antibodies comprise human and murine antibody fragments, generally human constant and mouse variable regions.

The phrase “complementarity determining region” or the term “CDR” refers to amino acid sequences which together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site (See, e.g., Chothia et al., J. Mol. Biol. 196:901 917 (1987); Kabat et al., U.S. Dept. of Health and Human Services NIH Publication No. 91 3242 (1991)). The phrase “constant region” refers to the portion of the antibody molecule that confers effector functions. In the present invention, mouse constant regions are preferably substituted by human constant regions. The constant regions of the subject antibodies are derived from human immunoglobulins. The heavy chain constant region can be selected from any of the five isotypes: alpha, delta, epsilon, gamma or mu.

The antibodies of the present invention are said to be immunospecific or specifically binding if they bind to antigen with a K_(a) of greater than or equal to about 10⁶M⁻¹ preferably greater than or equal to about 10⁷M⁻¹, more preferably greater than or equal to about 10⁸M⁻¹, and most preferably greater than or equal to about 10⁹M⁻¹, 10¹⁹M⁻¹, 10¹¹M⁻¹ or 10¹²M⁻¹. The anti-OSM antibodies may bind to different naturally occurring forms of OSM, including those expressed by the host's/subject's tissues as well as that expressed by the tumor. The monoclonal antibodies disclosed herein, such as RX1, 5H4, MC1, or MC3 antibody, have affinity for OSM and are characterized by a dissociation equilibrium constant (K^(d)) of at least 10⁻⁴ M, preferably at least about 10⁻⁷ M to about 10⁻⁸ M, more preferably at least about 108 M, 10^(10M), 10^(−11M) or 10^(−12M). Such affinities may be readily determined using conventional techniques, such as by equilibrium dialysis; by using the BIAcore 2000 instrument, using general procedures outlined by the manufacturer; by radioimmunoassay using ¹²⁵I labeled OSM; or by another method known to the skilled artisan. The affinity data may be analyzed, for example, by the method of Scatchard et al., Ann N.Y. Acad. Sci., 51:660 (1949). Thus, it will be apparent that preferred OSM antibodies will exhibit a high degree of specificity for OSM and will bind with substantially lower affinity to other molecules.

The antigen to be used for production of antibodies may be, e.g., intact OSM or a fragment of OSM that retains the desired epitope, optionally fused to another polypeptide that allows the epitope to be displayed in its native conformation. Alternatively, cells expressing OSM at their cell surface can be used to generate antibodies. Such cells can be transformed to express OSM or may be other naturally occurring cells that express OSM. Other forms of OSM useful for generating antibodies will be apparent to those skilled in the art.

Anti-OSM antibodies are known in the art and disclosed in US20130251724 and US20140099315, the disclosures of which are incorporated herein by reference.

C. OSM Muteins

The invention further provides OSM muteins that may be used as OSM antagonists according to the methods of the invention.

“Fragment” as used herein means a portion of the intact native molecule; for example, a fragment polypeptide is a fragment of the native polypeptide in which one or more amino acids from either the N-terminal or C-terminal have been deleted.

“Mutein” as used herein with respect to polypeptides means a variant of the intact native molecule or a variant of a fragment of the native molecule, in which one or more amino acids have been substituted, inserted or deleted. Such substitutions, insertions or deletions can be at the N-terminus, C-terminus or internal to the molecule. Thus the term “muteins” includes within its scope fragments of the native molecule. Insertional muteins include fusions at the N- or C-terminus, e.g. fusion to the Fc portion of an immunoglobulin to increase half-life.

Preferred muteins according to the invention exhibit at least about 65%, 70%. 75%, 80%, 85%, 90%, 95%, 97% or more sequence identity (homology) to the native polypeptide, as determined by the Smith-Waterman homology search algorithm (Meth. Mol. Biol. 70:173-187 (1997)) as implemented in the MSPRCH program (Oxford Molecular) using an affine gap search with the following search parameters: gap open penalty of 12, and gap extension penalty of 1. Other well-known and routinely used homology/identity scanning algorithm programs include Pearson and Lipman, PNAS USA, 85:2444-2448 (1988); Lipman and Pearson, Science, 222:1435 (1985); Devereaux et al., Nuc. Acids Res., 12:387-395 (1984); or the BLASTP, BLASTN or BLASTX algorithms of Altschul, et al., Mol. Biol., 215:403-410 (1990). Computerized programs using these algorithms are also available and include, but are not limited to: GAP, BESTFIT, BLAST, FASTA and TFASTA, which are commercially available from the Genetics Computing Group (GCG) package, Version 8, Madison Wis., USA; and CLUSTAL in the PC/Gene program by Intellegenetics, Mountain View Calif. Preferably, the percentage of sequence identity is determined by using the default parameters determined by the program.

“Modification” as used herein means any modification of the native polypeptide, fragment or mutein, such as glycosylation, phosphorylation, polymer conjugation (such as with polyethylene glycol), or other addition of foreign moieties, so long as the desired activity (agonist or antagonist) is retained.

In yet another embodiment, the OSM mutein comprises one or more of binding sites 1, 2, or 3, or portions thereof involved in receptor-binding, alone or fused to other polypeptides that allow display of the fragments in proper three-dimensional conformation.

Muteins containing any desired conservative and/or non-conservative muteins are readily prepared using techniques well known in the art, including recombinant production or chemical synthesis.

Conservative substitutions, particularly substitutions outside of regions directly involved in ligand-receptor binding, are not expected to significantly change the binding properties of the OSM muteins (or OSMR muteins). Amino acids can be classified according to physical properties and contribution to secondary and tertiary protein structure. A conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties. Exemplary conservative substitutions are set out in Table 2 (from WO 97/09433, page 10, published Mar. 13, 1997 (PCT/GB96/02197, filed Sep. 6, 1996), immediately below.

The availability of a DNA sequence encoding OSM permits the use of various expression systems to produce the desired polypeptides. Construction of expression vectors and recombinant production from the appropriate DNA sequences are performed by methods well known in the art. These techniques and various other techniques are generally performed according to Sambrook et al., Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989), and Kriegler, M., Gene Transfer and Expression, A Laboratory Manual, Stockton Press, New York (1990), both of which are incorporated herein by reference.

Certain modifications to the primary sequence of OSM can be made by deletion, addition, or alteration of the amino acids encoded by the DNA sequence without destroying the desired structure (e.g., the receptor binding ability of OSM) in accordance with well-known recombinant DNA techniques. Further, a skilled artisan will appreciate that individual amino acids may be substituted or modified by oxidation, reduction or other modification, and the polypeptide may be cleaved to obtain fragments that retain the active binding site and structural information. Such substitutions and alterations result in polypeptides having an amino acid sequence which falls within the definition of polypeptide “having substantially the same amino acid sequence” as the mature OSM SEQ ID NO:1 and 2.

Polypeptides may be produced by chemical synthesis or recombinant production techniques known in the art.

The relatedness of proteins can also be characterized through the relatedness of their encoding nucleic acids. Methods to determine identity and/or similarity of polynucleotide sequences are described above. In addition, methods to determine similarity of polynucleotide sequences through testing their ability to hybridize under moderately or highly stringent conditions may be determined as follows. Exemplary moderately stringent hybridization conditions are as follows: hybridization at 42° C. in a hybridization solution comprising 50% formamide, 1% SDS, 1 M NaCl, 10% Dextran sulfate, and washing twice for 30 minutes at 60° C. in a wash solution comprising 0.1×SSC and 1% SDS. Highly stringent conditions include washes at 68° C. in a wash solution comprising 0.1×SSC and 1% SDS. It is understood in the art that conditions of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration as described in the art (Ausubel, et al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10). Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be calculated as described in Sambrook et al., (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N.Y. (1989), pp. 9.47 to 9.51.

D. OSM Gene Therapy

Delivery of a therapeutic protein to appropriate cells can be effected via gene therapy ex vivo, in situ, or in vivo by use of any suitable approach known in the art, including by use of physical DNA transfer methods (e.g., liposomes or chemical treatments) or by use of viral vectors (e.g., adenovirus, adeno-associated virus, or a retrovirus). Antisense compounds and methods of using them are also provided by the present invention. The level of OSM or OSMR activity may be reduced by using well-known antisense, gene “knock-out,” ribozyme, triple helix or RNAi methods to decrease the level gene expression. Techniques for the production and use of such molecules are well known to those of skill in the art.

As used herein, the term “peptidomimetic” is a non-peptide compound that comprises an assembly of amino acid side chains, or pharmacophores, or suitable derivatives thereof, that are supported on a scaffold such that the spatial orientation of the pharmacophores substantially mimic the bioactive conformation of a natural peptide. For example, a peptidomimetic may lack amino acids or peptide bonds but retain the particular three-dimensional arrangement of peptide chain groups from the parent peptide that is required for binding activity. The scaffold may comprise a bicyclic, tricyclic or higher polycyclic carbon or heteroatom skeleton, or may be based on one or more ring structures (e.g., pyridine, imidazole, etc.) or amide bonds. This scaffold may be linked by spacers to an acidic group (e.g. a carboxylic acid functional group) at one end and a basic group (e.g. an N-containing moiety such as amidine or guanidine) at the other end of the core. Exemplary techniques for synthesizing peptidomimetics are described in U.S. patent application no. 20030199531 published Oct. 23, 2003, U.S. Patent Application No. 20030139348 published Jul. 24, 2003.

In addition to antibodies and other proteins, this invention also contemplates alternative OSM antagonists including, but not limited to, peptides or small organic molecules that are also effective in inhibiting the interaction between OSM and OSMR or the activation of OSMR.

II.) Combination Therapy

Concurrent administration of two therapeutic agents according to the present invention, such as an OSM antagonist and a second anti-osteoclast agent, does not require that the agents be administered at the same time or by the same route, as long as there is an overlap in the time period during which the agents are exerting their therapeutic effect. Simultaneous or sequential administration is contemplated, as is administration on different days or weeks.

The discovery of a significant time lag to observe therapeutic effect after commencing treatment with an OSM antibody (an exemplary OSM antagonist) makes desirable the co-administration of a second anti-osteoclast agent with quicker onset of action during this transition period. During the transition period, the two agents must be administered at a monotherapeutically effective amount. Subsequent to the transition period, the second anti-osteoclast agent may be discontinued or reduced in dosage. If the OSM antagonist and second anti-osteoclast agent exert synergistic effects, the dose of one or both may be lowered after the transition period.

Compositions of the invention are administered to a mammal already suffering from, or predisposed to, cancer and associated tumor cell detachment, proliferation and/or metastasis, in an amount sufficient to prevent or at least partially arrest the development of such disease. An amount of a therapeutic agent adequate to accomplish this when the therapeutic agent is given alone (not in combination with a second therapeutic agent) is defined as a “monotherapeutically effective dose.”

In the combination therapy methods of the present invention, the OSM antagonist, such as the OSM antibody, and the second anti-osteoclast agent may be administered simultaneously or at different time. The two agents can be administered, for example, within 8 hours, 1 day, 14 days, 30 days, 3 months, 6 months, 9 months or 1 year of each other.

Exemplary second anti-osteoclast agents include bisphosphonates, including but not limited to zoledronate, pamidronate, clodronate, etidronate, tiludronate, alendronate, ibandronate or risedronate. Exemplary other anti-osteoclast agents include bisphosphonates, PTHrP neutralizing agents (e.g., antibody, antisense, siRNA), cathepsin K inhibitors, MIP-1-{acute over (α)} antagonists, RANK/RANKL neutralizing agents (e.g., anti-RANK antibody, such as AMG-162, or antisense, soluble RANKL receptor or muteins thereof), RANKL vaccine, osteoprotegrin (OPG), platelet-derived growth factors (PDGF), src kinase inhibitors, gallium maltolate, and matrix metalloproteinase (MMP) inhibitors.

Exemplary doses of bisphosphonates include the intravenous administration of 4 mg. Lesser dosages may also be administered including 3.5 mg, 3.3 mg or 3.0 mg. Other routes of administration are possible including subcutaneous and as described in WO 02/087555. Effective amounts of a OSM antibody will vary and depend on the severity of the disease and the weight and general state of the patient being treated, but generally range from about 1.0 mg/kg to about 100 mg/kg body weight, or about 10 mg/kg to about 30 mg/kg, with dosages of from about 0.1 mg/kg to about 10 mg/kg or about 1 mg/kg to about 10 mg/kg per application being more commonly used. For example, about 10 mg/kg to 5 mg/kg or about 30 mg/kg to 1 mg/kg of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. Administration is daily, on alternating days, weekly or less frequently, as necessary depending on the response to the disease and the patient's tolerance of the therapy. Maintenance dosages over a longer period of time, such as 4, 5, 6, 7, 8, 10 or 12 weeks or longer may be needed until a desired suppression of disease symptoms occurs, and dosages may be adjusted as necessary. The progress of this therapy is easily monitored by conventional techniques and assays.

Although the methods of the present invention may be useful for all stages of cancers, they may be particularly appropriate in advanced or metastatic cancers. Combining the therapy method with a chemotherapeutic or radiation regimen may be preferred in patients that have not received chemotherapeutic treatment, whereas treatment with the therapy method of the present invention may be indicated for patients who have received one or more chemotherapies. Additionally, the therapy methods of the present invention can also enable the use of reduced dosages of concomitant chemotherapy, particularly in patients that do not tolerate the toxicity of the chemotherapeutic agent very well.

The method of the invention contemplates the administration of single anti-OSM antibodies, as well as combinations, or “cocktails”, of different antibodies. Such antibody cocktails may have certain advantages in as much as they contain antibodies which exploit different effector mechanisms or combine directly cytotoxic antibodies with antibodies that rely on immune effector functionality. Such antibodies in combination may exhibit synergistic therapeutic effects.

The methods of the invention can be used in combination with yet other therapeutics, such as cancer therapeutics. Exemplary cancer therapeutic agents and/or procedures, include but are not limited to various chemotherapeutic agents, androgen-blockers, and immune modulators (e.g., IL-2, GOSM, SLC), Bisphosphonate(s) (e.g.,

Aredia (i.e., pamidronate, pamidronic acid, disodium pamidronate, pamidronate disodium pentahydrate); Zometa (i.e., Aclasta, zoledronic acid, zoledronate); Clondronate (i.e., Bonefos, Loron, clodronate disodium, sodium clondronate); Fosamax (i.e., alendronate, alendronate sodium salt trihydrate, alendronic acid); Fosavance (i.e., Fosamax formulated with vitamin D); Bondronat or Bonviva or Boniva (i.e., ibandronate, ibandronic acid, ibandronate sodium); Actonel (i.e., risedronate, risedronate sodium, risendronic acid); Didronel or Didrocal (i.e., etidronate, etidronic acid, etidronate disodium); Nerixia (i.e., neridronate, neridronic acid); Skelid (i.e., tiludronate, tiludronic acid); dimethyl-APD (i.e., olpadronate, olpadronic acid); and medronic acid or medronate), surgery, radiation, cytotoxic chemotherapy, hormone therapy (e.g., Tamoxifen; anti-Androgen therapy), antibody therapy (e.g., antibodies to RANKL/RANK neutralizing; PTHrP neutralizing, anti-Her2, anti-CD20, anti-CD40, CD22, VEGF, IGFR-1, EphA2, HAAH, TMEFF2, CAIX antibodies), therapeutic protein therapy (e.g., soluble RANKL receptor; OPG, and PDGF and MMP inhibitors), small molecule drug therapy (e.g., Src-kinase inhibitor), kinase inhibitors of growth factor receptors, or RANKL inhibitors, oligonucleotides therapy (e.g., RANKL or RANK or PTHrP Anti-sense), gene therapy (e.g. RANKL or RANK inhibitors, such as anti-RANKL antibodies), peptide therapy (e.g. muteins of RANKL) as well as those proteins, peptides, compounds, and small molecules described herein.

Cancer chemotherapeutic agents include, without limitation, alkylating agents, such as carboplatin and cisplatin; nitrogen mustard alkylating agents; nitrosourea alkylating agents, such as carmustine (BCNU); antimetabolites, such as methotrexate; folinic acid; purine analog antimetabolites, mercaptopurine; pyrimidine analog antimetabolites, such as fluorouracil (5-FU) and gemcitabine (Gemzar®.); hormonal antineoplastics, such as goserelin, leuprolide, and tamoxifen; natural antineoplastics, such as aldesleukin, interleukin-2, docetaxel, eloposide (VP-16), interferon alfa, paclitaxel (Taxol®), and tretinoin (ATRA); antibiotic natural antineoplastics, such as bleomycin, dactinomycin, daunorubicin, doxorubicin, daunomycin and mitomycins including mitomycin C; and vinca alkaloid natural antineoplastics, such as vinblastine, vincristine, vindesine; hydroxyurea; aceglatone, adriamycin, ifosfamide, enocitabine, epitiostanol, aclarubicin, ancitabine, nimustine, procarbazine hydrochloride, carboquone, carboplatin, carmofur, chromomycin A3, antitumor polysaccharides, antitumor platelet factors, cyclophosphamide (Cytoxin®); Schizophyllan, Cytarabine® (cytosine arabinoside), dacarbazine, thioinosine, thiotepa, tegafur, dolastatins, dolastatin analogs such as auristatin, CPT-11 (irinotecan), mitozantrone, vinorelbine, teniposide, aminopterin, caminomycin, esperamicins (See, e.g., U.S. Pat. No. 4,675,187), neocarzinostatin, OK-432, bleomycin, furtulon, broxuridine, busulfan, honvan, peplomycin, bestatin (Ubenimex®.), interferon-β, mepitiostane, mitobronitol, melphalan, laminin peptides, lentinan, Coriolus versicolor extract, tegafur/uracil, estramustine (estrogen/mechlorethamine).

Further, additional agents used as therapy for cancer patients include EPO, G-CSF, ganciclovir; antibiotics, leuprolide; meperidine; zidovudine (AZT); interleukins 1 through 18, including mutants and analogues; interferons or cytokines, such as interferons α, β, and γ hormones, such as luteinizing hormone releasing hormone (LHRH) and analogues and, gonadotropin releasing hormone (GnRH); growth factors, such as transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), nerve growth factor (NGF), growth hormone releasing factor (GHRF), epidermal growth factor (EGF), fibroblast growth factor homologous factor (FGFHF), hepatocyte growth factor (HGF), and insulin growth factor (IGF); tumor necrosis factor-α & β (TNF-α & β); invasion inhibiting factor-2 (IIF-2); bone morphogenetic proteins 1-7 (BMP 1-7); somatostatin; thymosin-α-1; γ-globulin; superoxide dismutase (SOD); complement factors; anti-angiogenesis factors: antigenic materials; and pro-drugs.

Prodrug refers to a precursor or derivative form of a pharmaceutically active substance that is less cytotoxic or non-cytotoxic to tumor cells compared to the parent drug and is capable of being enzymatically activated or converted into an active or the more active parent form. See, e.g., Wilman, “Prodrugs in Cancer Chemotherapy” Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Belfast (1986) and Stella et al., “Prodrugs: A Chemical Approach to Targeted Drug Delivery,” Directed Drug Delivery, Borchardt et al., (ed.), pp. 247-267, Humana Press (1985). Prodrugs include, but are not limited to, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, β-lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted into the more active cytotoxic free drug. Examples of cytotoxic drugs that can be derivatized into a prodrug form for use herein include, but are not limited to, those chemotherapeutic agents described above.

III). Compositions Comprising OSM Antagonists

Compositions for inhibiting or reducing tumor cell detachment, proliferation and/or metastasis are provided. Preferred compositions are those that interfere, inhibit, reduce or block OSM protein function. In one embodiment the composition includes an antagonist of OSM, or its target gp130 or a combination thereof. A preferred OSM protein antagonist includes, but is not limited to a small molecule that sterically interacts with binding site 1 of OSM.

Other embodiments provide compositions for inhibiting or reducing OSM activity, such as antibodies which bind and thus inhibit OSM activity, proteins, muteins, and/or nucleic acid compositions which may interfere with OSM production or may encode antibodies and other protein inhibitors themselves.

Another embodiment is directed to compositions comprising an OSM antagonist in an amount effective to inhibit OSM activity relative to a control. It will be appreciated that a control includes cells or organisms that are not treated with the disclosed compositions.

In another embodiment, the disclosed OSM protein antagonists selectively interact with a region disclosed herein as active site 1 of the OSM protein.

The compositions are administered to an individual in need of treatment or prophylaxis of at least one symptom or manifestation (since disease can occur/progress in the absence of symptoms) of cancer or cellular hyperproliferation. In one embodiment, the compositions are administered in an effective amount to inhibit OSM mediated cellular activity and thereby inhibit or reduce tumor cell detachment, proliferation and/or metastasis. The amount of inhibition can be determined relative to a control, for example cells that are not treated with the inhibitor. Methods for measuring inhibition OSM activity are provided in the Examples.

A. Formulations

The compounds are preferably employed for therapeutic uses in combination with a suitable pharmaceutical carrier. Such compositions include an effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. The formulation is made to suit the mode of administration. Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions containing the nucleic acids some of which are described herein.

The compounds may be in a formulation for administration topically, locally or systemically in a suitable pharmaceutical carrier. Remington's Pharmaceutical Sciences, 15th Edition by E. W. Martin (Mark Publishing Company, 1975), discloses typical carriers and methods of preparation. The compound may also be encapsulated in suitable biocompatible microcapsules, microparticles or microspheres formed of biodegradable or non-biodegradable polymers or proteins or liposomes for targeting to cells. Such systems are well known to those skilled in the art and may be optimized for use with the appropriate nucleic acid.

Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, or thickeners can be used as desired.

Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions, solutions or emulsions that can include suspending agents, solubilizers, thickening agents, dispersing agents, stabilizers, and preservatives. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.

Preparations include sterile aqueous or nonaqueous solutions, suspensions and emulsions, which can be isotonic with the blood of the subject in certain embodiments. Examples of nonaqueous solvents are polypropylene glycol, polyethylene glycol, vegetable oil such as olive oil, sesame oil, coconut oil, arachis oil, peanut oil, mineral oil, injectable organic esters such as ethyl oleate, or fixed oils including synthetic mono or di-glycerides. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, 1,3-butandiol, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, antioxidants, chelating agents and inert gases and the like. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. Those of skill in the art can readily determine the various parameters for preparing and formulating the compositions without resort to undue experimentation.

The compound alone or in combination with other suitable components, can also be made into aerosol formulations (i.e., they can be “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. For administration by inhalation, the compounds are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant.

In some embodiments, the compound described above may include pharmaceutically acceptable carriers with formulation ingredients such as salts, carriers, buffering agents, emulsifiers, diluents, excipients, chelating agents, fillers, drying agents, antioxidants, antimicrobials, preservatives, binding agents, bulking agents, silicas, solubilizers, or stabilizers. In one embodiment, the compounds are conjugated to lipophilic groups like cholesterol and lauric and lithocholic acid derivatives with C32 functionality to improve cellular uptake. For example, cholesterol has been demonstrated to enhance uptake and serum stability of siRNA in vitro (Lorenz, et al., Bioorg. Med. Chem. Lett. 14(19):4975-4977 (2004)) and in viva (Soutschek, et al., Nature 432(7014):173-178 (2004)). Other groups that can be attached or conjugated to the compounds described above to increase cellular uptake, include acridine derivatives; cross-linkers such as psoralen derivatives, azidophenacyl, proflavin, and azidoproflavin; artificial endonucleases; metal complexes such as EDTA-Fe(II) and porphyrin-Fe(II); alkylating moieties; enzymes such as alkaline phosphatase; terminal transferases; abzymes; cholesteryl moieties; lipophilic carriers; peptide conjugates; long chain alcohols; phosphate esters; radioactive markers; non-radioactive markers; carbohydrates; and polylysine or other polyamines. U.S. Pat. No. 6,919,208 to Levy, et al., also described methods for enhanced delivery. These pharmaceutical formulations may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

B. Methods of Administration

In general, methods of administering compounds are well known in the art. The compositions can be administered by a number of routes including, but not limited to: oral, intravenous, intraperitoneal, intramuscular, transdermal, subcutaneous, topical, sublingual, or rectal means. Compounds can also be administered via liposomes. Such administration routes and appropriate formulations are generally known to those of skill in the art.

Administration of the formulations described herein may be accomplished by any acceptable method which allows the compounds to reach its target. The particular mode selected will depend of course, upon factors such as the particular formulation, the severity of the state of the subject being treated, and the dosage required for therapeutic efficacy. As generally used herein, an “effective amount” is that amount which is able to treat one or more symptoms of age related disorder, reverse the progression of one or more symptoms of age related disorder, halt the progression of one or more symptoms of age related disorder, or prevent the occurrence of one or more symptoms of age related disorder in a subject to whom the formulation is administered, as compared to a matched subject not receiving the compound. The actual effective amounts of compound can vary according to the specific compound or combination thereof being utilized, the particular composition formulated, the mode of administration, and the age, weight, condition of the individual, and severity of the symptoms or condition being treated.

Any acceptable method known to one of ordinary skill in the art may be used to administer a formulation to the subject. The administration may be localized (i.e., to a particular region, physiological system, tissue, organ, or cell type) or systemic, depending on the condition being treated.

Injections can be e.g., intravenous, intradermal, subcutaneous, intramuscular, or intraperitoneal. The composition can be injected intradermally for treatment or prevention of age related disorder, for example. In some embodiments, the injections can be given at multiple locations. Implantation includes inserting implantable drug delivery systems, e.g., microspheres, hydrogels, polymeric reservoirs, cholesterol matrixes, polymeric systems, e.g., matrix erosion and/or diffusion systems and non-polymeric systems, e.g., compressed, fused, or partially-fused pellets. Inhalation includes administering the composition with an aerosol in an inhaler, either alone or attached to a carrier that can be absorbed. For systemic administration, it may be preferred that the composition is encapsulated in liposomes.

The formulations may be delivered using a bioerodible implant by way of diffusion or by degradation of the polymeric matrix. In certain embodiments, the administration of the formulation may be designed so as to result in sequential exposures to the active agent over a certain time period, for example, hours, days, weeks, months or years. This may be accomplished, for example, by repeated administrations of a formulation or by a sustained or controlled release delivery system in which the active agent is delivered over a prolonged period without repeated administrations. Administration of the formulations using such a delivery system may be, for example, by oral dosage forms, bolus injections, transdermal patches or subcutaneous implants. Maintaining a substantially constant concentration of the composition may be preferred in some cases.

Other delivery systems suitable include time-release, delayed release, sustained release, or controlled release delivery systems. Such systems may avoid repeated administrations in many cases, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include, for example, polymer-based systems such as polylactic and/or polyglycolic acids, polyanhydrides, polycaprolactones, copolyoxalates, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and/or combinations of these. Microcapsules of the foregoing polymers containing nucleic acids are described in, for example, U.S. Pat. No. 5,075,109. Other examples include nonpolymer systems that are lipid-based including sterols such as cholesterol, cholesterol esters, and fatty acids or neutral fats such as mono-, di- and triglycerides; hydrogel release systems; liposome-based systems; phospholipid based-systems; silastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; or partially fused implants. Specific examples include erosional systems in which the OSM protein antagonist is contained in a formulation within a matrix (for example, as described in U.S. Pat. Nos. 4,452,775, 4,675,189, 5,736,152, 4,667,013, 4,748,034 and 5,239,660), or diffusional systems in which an active component controls the release rate (for example, as described in U.S. Pat. Nos. 3,832,253, 3,854,480, 5,133,974 and 5,407,686). The formulation may be as, for example, microspheres, hydrogels, polymeric reservoirs, cholesterol matrices, or polymeric systems. In some embodiments, the system may allow sustained or controlled release of the composition to occur, for example, through control of the diffusion or erosion/degradation rate of the formulation containing the OSM protein antagonist. In addition, a pump-based hardware delivery system may be used to deliver one or more embodiments.

Examples of systems in which release occurs in bursts includes, e.g., systems in which the composition is entrapped in liposomes which are encapsulated in a polymer matrix, the liposomes being sensitive to specific stimuli, e.g., temperature, pH, light or a degrading enzyme and systems in which the composition is encapsulated by an ionically-coated microcapsule with a microcapsule core degrading enzyme. Examples of systems in which release of the inhibitor is gradual and continuous include, e.g., erosional systems in which the composition is contained in a form within a matrix and effusional systems in which the composition permeates at a controlled rate, e.g., through a polymer. Such sustained release systems can be e.g., in the form of pellets, or capsules.

Use of a long-term release implant may be particularly suitable in some embodiments. “Long-term release,” as used herein, means that the implant containing the composition is constructed and arranged to deliver therapeutically effective levels of the composition for at least 30 or 45 days, and preferably at least 60 or 90 days, or even longer in some cases. Long-term release implants are well known to those of ordinary skill in the art, and include some of the release systems described above.

C. Effective Dosages

Dosages for a particular individual can be determined by one of ordinary skill in the art using conventional considerations, (e.g. by means of an appropriate, conventional pharmacological protocol). A physician may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. The dose administered to an individual is sufficient to effect a beneficial therapeutic response in the individual over time, or, e.g., to reduce symptoms, or other appropriate activity, depending on the application. The dose is determined by the efficacy of the particular formulation, and the activity, stability or serum half-life of the OSM protein antagonist employed and the condition of the individual, as well as the body weight or surface area of the individual to be treated. The size of the dose is also determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, formulation, or the like in a particular individual.

Formulations are administered at a rate determined by the LD50 of the relevant formulation, and/or observation of any side-effects of the compositions at various concentrations, e.g., as applied to the mass and overall health of the individual. Administration can be accomplished via single or divided doses.

In vitro models can be used to determine the effective doses of the compositions as a potential cancer treatment, as described in the examples. In determining the effective amount of the compound to be administered in the treatment or prophylaxis of disease the physician evaluates circulating plasma levels, formulation toxicities, and progression of the disease. For the disclosed compositions, the dose administered to a 70 kilogram individual is typically in the range equivalent to dosages of currently-used therapeutic antibodies such as Avastin®, Erbitux® and Herceptin®.

The formulations described herein can supplement treatment conditions by any known conventional therapy, including, but not limited to, antibody administration, vaccine administration, administration of cytotoxic agents, natural amino acid polypeptides, nucleic acids, nucleotide analogues, and biologic response modifiers. Two or more combined compounds may be used together or sequentially. For example, the compositions can also be administered in therapeutically effective amounts as a portion of an anti-cancer cocktail. Anti-cancer cocktails can include therapeutics to treat cancer or angiogenesis of tumors.

IV). Methods of Treatment

The disclosed compositions can be administered to a subject in need thereof to treat, alleviate, or reduce one or more symptoms associated with cancer or other forms of cellular hyperproliferation. The compositions can be administered locally or systemically to inhibit tumor cell detachment, proliferation and/or metastasis. The types of cancer that can be treated with the provided compositions and methods include, but are not limited to, the following: bladder, brain, breast, cervical, colorectal, esophageal, kidney, liver, lung, nasopharangeal, pancreatic, prostate, skin, stomach, uterine, ovarian, and testicular. In a preferred embodiment the cancer is prostate or breast cancer. Administration is not limited to the treatment of an existing tumor but can also be used to prevent or lower the risk of developing such diseases in an individual, i.e., for prophylactic use. Potential candidates for treatment include individuals with a high risk of developing cancer, i.e., with a personal or familial history of certain types of cancer.

Malignant tumors which may be treated are classified herein according to the embryonic origin of the tissue from which the tumor is derived. Carcinomas are tumors arising from endodermal or ectodermal tissues such as skin or the epithelial lining of internal organs and glands. Sarcomas, which arise less frequently, are derived from mesodermal connective tissues such as bone, fat, and cartilage. The leukemias and lymphomas are malignant tumors of hematopoietic cells of the bone marrow. Leukemias proliferate as single cells, whereas lymphomas tend to grow as tumor masses. Malignant tumors may show up at numerous organs or tissues of the body to establish a cancer.

In one embodiment, the subject is subjected to primary surgery related to the cancer. In another embodiment, administering the pharmaceutical formulation takes place before, during or after the primary surgery. In yet another embodiment, the cancer comprises a solid cancer. In yet another embodiment, the solid cancer is selected from the group consisting of breast cancer and prostate cancer.

V). Methods for Screening for Inhibitors of Tumor Cell Detachment, Proliferation and Metastasis

Methods for identifying inhibitors of tumor cell detachment, proliferation and/or metastasis are provided and utilize well known techniques and reagents. The inhibitor reduces, inhibits, blocks, or interferes with OSM protein function, expression, or bioavailability.

In some embodiments, the assays can include random screening of large libraries of test compounds. The test compounds are, in a preferred embodiment non-protein small molecules. The term “small molecule” refers to compounds less than 1,000 daltons, typically less than 500 daltons. Alternatively, the assays may be used to focus on particular classes of compounds suspected of inhibiting OSM activity in cells, tissues, organs, or systems.

Assays can include determinations of OSM protein expression, protein expression, protein activity, signal transduction, or binding activity. Other assays can include determinations of OSM protein nucleic acid transcription or translation, for example mRNA levels, mRNA stability, mRNA degradation, transcription rates, and translation rates.

In one embodiment, the identification of an inhibitor of tumor cell detachment, proliferation and/or metastasis is based on the function of OSM in the presence and absence of a test compound. The test compound or modulator can be any substance that alters or is believed to alter the function of OSM. Typically, an inhibitor will be selected that reduces, eliminates, or inhibits OSM and the OSM initiated regulatory pathway.

One exemplary method includes contacting OSM protein with at least a first test compound, and assaying for an interaction between OSM protein and the first test compound with an assay. The assaying can include determining inhibition of OSM interaction with gp-130.

Specific assay endpoints or interactions that may be measured in the disclosed embodiments include assaying for OSM, modulation, down or up regulation or turnover. These assay endpoints may be assayed using standard methods such as FACS, FACE, ELISA, Northern blotting and/or Western blotting. Moreover, the assays can be conducted in cell free systems, in isolated cells, genetically engineered cells, immortalized cells, or in organisms such as transgenic animals.

Other screening methods include using labeled OSM protein to identify a test compound. OSM can be labeled using standard labeling procedures that are well known and used in the art. Such labels include, but are not limited to, radioactive, fluorescent, biological and enzymatic tags.

Another embodiment provides a method for identifying an inhibitor of tumor cell detachment, proliferation and/or metastasis by determining the effect a test compound has OSM activity. For example isolated cells or whole organisms expressing OSM or both can be contacted with a test compound. OSM activity can be determined using standard biochemical techniques such as immunodetection. Suitable cells for this assay include, but are not limited to, cancer cells, immortalized cell lines, primary cell culture, or cells engineered to express OSM proteins, for example cells from mammals such as humans. Compounds that inhibit OSM activity can be selected.

Another embodiment provides for in vitro assays for the identification of inhibitors of tumor cell detachment, proliferation and/or metastasis. Such assays generally use isolated molecules, can be run quickly and in large numbers, thereby increasing the amount of information obtainable in a short period of time. A variety of vessels may be used to run the assays, including test tubes, plates, dishes and other surfaces such as dipsticks or beads.

One example of a cell free assay is a binding assay. While not directly addressing function, the ability of a modulator to bind to a target molecule in a specific fashion is strong evidence of a related biological effect. Such a molecule can bind to OSM protein and inhibit its biological functions. The binding of a molecule to a target may, in and of itself, be inhibitory, due to steric, allosteric or charge—charge interactions or inactivation of OSM protein. The target may be either free in solution, fixed to a support, expressed in or on the surface of a cell. Either the target or the compound may be labeled, thereby permitting determining of binding. Usually, the target will be the labeled species, decreasing the chance that the labeling will interfere with or enhance binding. Competitive binding formats can be performed in which one of the agents is labeled, and one may measure the amount of free label versus bound label to determine the effect on binding.

A technique for high throughput screening of compounds is described in WO 84/03564. Large numbers of small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. Bound polypeptide is detected by various methods.

Other embodiments include methods of screening compounds for their ability to inhibit the function of OSM proteins. Various cell lines can be utilized for such screening assays, including cells specifically engineered for this purpose. Furthermore, those of skill in the art will appreciate that stable or transient transfections, which are well known and used in the art, may be used in the disclosed embodiments.

For example, a transgenic cell comprising an expression vector can be generated by introducing the expression vector into the cell. The introduction of DNA into a cell or a host cell is well known technology in the field of molecular biology and is described, for example, in Sambrook et al., Molecular Cloning 3rd Ed. (2001). Methods of transfection of cells include calcium phosphate precipitation, liposome mediated transfection, DEAE dextran mediated transfection, electroporation, ballistic bombardment, and the like. Alternatively, cells may be simply transfected with the disclosed expression vector using conventional technology described in the references and examples provided herein. The host cell can be a prokaryotic or eukaryotic cell, or any transformable organism that is capable of replicating a vector and/or expressing a heterologous gene encoded by the vector. Numerous cell lines and cultures are available for use as a host cell, and they can be obtained through the American Type Culture Collection (ATCC), which is an organization that serves as an archive for living cultures and genetic materials (www.atcc.org).

A host cell can be selected depending on the nature of the transfection vector and the purpose of the transfection. A plasmid or cosmid, for example, can be introduced into a prokaryote host cell for replication of many vectors. Bacterial cells used as host cells for vector replication and/or expression include DH5.alpha., JM109, and KCB, as well as a number of commercially available bacterial hosts such as SURE® Competent Cells and SOLOPACK Gold Cells (STRATAGENE, La Jolla, Calif.). Alternatively, bacterial cells such as E. coli LE392 could be used as host cells for phage viruses. Eukaryotic cells that can be used as host cells include, but are not limited to, yeast, insects and mammals. Examples of mammalian eukaryotic host cells for replication and/or expression of a vector include, but are not limited to, HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12. Examples of yeast strains include YPH499, YPH500 and YPH501. Many host cells from various cell types and organisms are available and would be known to one of skill in the art. Similarly, a viral vector may be used in conjunction with either an eukaryotic or prokaryotic host cell, particularly one that is permissive for replication or expression of the vector. Depending on the assay, culture may be required. The cell is examined using any of a number of different physiologic assays. Alternatively, molecular analysis may be performed, for example, looking at protein expression, mRNA expression (including differential display of whole cell or polyA RNA) and others.

In vivo assays involve the use of various animal models, including non-human transgenic animals that have been engineered to have specific defects, or carry markers that can be used to measure the ability of a test compound to reach and affect different cells within the organism. Due to their size, ease of handling, and information on their physiology and genetic make-up, mice are a preferred embodiment, especially for transgenic animals. However, other animals are suitable as well, including C. elegans, rats, rabbits, hamsters, guinea pigs, gerbils, woodchucks, cats, dogs, sheep, goats, pigs, cows, horses and monkeys (including chimps, gibbons and baboons). Assays for modulators may be conducted using an animal model derived from any of these species.

Determining the effectiveness of a compound in vivo may involve a variety of different criteria. Also, measuring toxicity and dose response can be performed in animals in a more meaningful fashion than in in vitro or in cyto assays.

VI.) The Role of OSM and Metastasis

The role of inflammation in invasion and metastasis, particularly of prostate tumors, is not well understood. However, several studies show a correlation between serum levels of the interleukin-6 (IL-6) family inflammatory cytokines and distant metastases. Oncostatin M (OSM) is an inflammatory modulator in the interleukin-6 (IL-6) cytokine family that can be associated with the metastatic potential of prostate carcinomas. OSM promotes human prostate cancer cell proliferation, epithelial-mesenchymal transition (EMT) and detachment in vitro. In prostate cancer cells, OSM can induce vascular endothelial growth factor (VEGF) and urokinase-type plasminogen activator (u-PA), two proteins suspected to be involved in tumor progression. In addition, a pattern of increased OSM expression can occur in high grade Gleason (aggressive) carcinomas. OSM's influence on prostate cancer has only been minimally studied in vitro. We determined that OSM promotes invasive capacity of prostate tumor cells and their metastasizing potential.

Androgen deprivation therapy is the standard course of treatment for prostate cancer. However, most prostate cancers treated through androgen deprivation therapy eventually recur. Moreover, prostate tumors with high Gleason scores can be metastatic and/or refractory to androgen deprivation therapy. Therefore, alternative therapies, such as the OSM inhibitors disclosed herein can be advantageous.

OSM can play a role in prostate cancer. OSM expression can be directly associated with metastatic potential in clinical prostate carcinoma, with increasing OSM and OSM receptor expression being found in higher Gleason grade tumors. In vitro studies have shown that OSM induces both vascular endothelial growth factor (VEGF) and urokinase-type plasminogen-activator (u-PA) expression in DU-145 PCa cells, each of which are implicated in tumor progression. In addition, the proliferation of the DU-145 and 22Rv1 prostate cancer cell lines increases with increasing OSM values. OSM can also induce the epithelial to the mesenchymal transition (EMT), cell detachment, and invasive capacity of DU-145 cells.

OSM has been implicated in tumor invasion and metastasis of other tumors as well. These other types of tumors can include, for example, ovarian and breast cancer. Hereinafter and in Examples 1-8, the inventors describe their detailed findings in relation to breast cancer, as these results can be readily extended to the understanding and treatment of prostate cancer.

We have studied the role of Oncostatin M (OSM) promoting the metastasis of breast tumors. OSM is a pro-inflammatory pleiotropic IL-6 family cytokine that plays a role in development, neurogenesis, liver regeneration, and haematopoiesis. OSM activates signaling pathways by binding its receptors, OSM receptor (3 (OSMRβ) or leukemia inhibitory factor receptor β (LIFRβ) dimerized with a common gp130 subunit. OSM also activates the JAK/STAT, MAPK, and PI3K/AKT pathways via binding its receptors. Moreover, OSM activates the stress-activated mitogen-activated protein kinases p38 and JNK.

In vitro studies examining the role of OSM signaling in breast cancer have suggested that this cytokine may increase the metastatic potential for breast epithelial cells. While OSM inhibits proliferation of various carcinomas including lung cancer, multiple myeloma and breast cancer, in other cancer types it actually increases proliferation. Though OSM's effect of tumor cell proliferation is not the same for any carcinoma, recent research suggests that this cytokine can promote invasion and metastasis. Specifically, OSM can function on various cancer cells in vitro to: 1) promote the transition from an epithelial to mesenchymal phenotype (EMT), 2) upregulate expression of proteases such as cathepsins, and matrix metalloproteinases (MMPs), 3) promote tumor cell-substrate invasion and detachment, and 4) induce the expression of vascular endothelial growth factor (VEGF), HIFla and other proangiogenic factors, 5) induce increased cancer cell stemness, suppress ER alpha expression, and promote S100A7 expression.

A role for OSM produced by tumor-associated immune cells can promote a metastatic phenotype in breast cancer cells in vitro. In response to breast cancer cells in vitro, macrophages and neutrophils collected from healthy human volunteers can express and secrete high levels of OSM, thereby supporting a role for OSM in the breast tumor microenvironment. Additionally, breast cancer cells alone secrete high levels of OSM in culture in addition to the immune cells. Taken together, these in vitro studies suggest a role for both autocrine and paracrine signaling by OSM in tumor metastatic potential, particularly during early stages of the metastatic cascade.

Transgenic and other mouse models of OSM can show its importance in the production of red blood cells and platelets, wound-healing in the heart and liver, bone homeostasis, inflammatory cell migration and infiltration into injured tissue, and leukocyte activation.

We discovered that in vivo OSM can increase mammary tumor metastases to bone and increase bone metastatic osteolysis. Thus, OSM can influence normal bone homeostatis and in the bone metastatic microenvironment during later stages of breast cancer metastasis. Increased OSM expression can also lead to changes in ECM remodeling during breast tissue involution.

More specifically, we investigated the effect of OSM on early stages of breast cancer metastasis. First, we established the expression pattern of OSM in human breast tissue using tissue microarrays. We showed that OSM is expressed at higher levels in Invasive Ductal Carcinoma (IDC) than the adjacent normal breast tissue, but at highest levels in ductal carcinoma in situ (DCIS), suggesting that OSM may play an important role in the early stages of breast tumor invasion and metastasis. In order to further investigate this feature in vivo, we utilized the syngeneic model of 4T1.2 mouse mammary tumor cells that when injected into Balb/c mice established a metastatic pattern similar to that seen in breast cancer patients. We showed that a reduced OSM expression in 4T1.2 cells (4T1.2-shOSM) is sufficient to inhibit the progression and final number and volume of metastases in the lung. In this orthotopic model, our results demonstrate that reduced OSM significantly increases survival post-primary tumor resection; however, bypassing the early stages of metastasis by injecting cells directly into the systemic circulation, did not. We confirmed OSM increases early stage metastatic potential in vitro by showing OSM induces 4T1.2 tumor cell detachment and migration. These findings were corroborated with an in vivo study demonstrating that when OSM is injected peri-tumorally in a mice harboring MDA-MB-231 mammary tumors, there is an increase in the number of circulating tumor cells as well as spontaneous metastasis to lung. Findings from these studies suggest that autocrine and paracrine OSM in the tumor microenvironment acts as a potent initiator of invasion and the early stages of metastasis. Therefore, modification of OSM levels in the tumor microenvironment can be a highly effective therapeutic strategy for halting the invasion and metastasis of breast cancer.

An intriguing finding of this study is that OSM epithelial expression is higher in earlier stages of ductal carcinoma of the breast (DCIS and IDC) compared to metastatic disease, which is consistent with the proposed role of OSM in vitro that it promotes the initiation of invasiveness of breast cancer. Higher levels of OSM and OSMR are seen in breast tissue as it progresses from ductal carcinoma in situ to invasive ductal carcinoma. Although OSM expression has been studied in various human tumors such as prostate cancer, ovarian cancer and keratocanthoma, the present study may provide additional insights into the role of OSM in breast cancer and in these other types of cancers. In breast cancer, in vivo research suggests a role for OSM in metastasis. OSM can promote bone metastases and bone destruction from the metastases and can promote the protein expression of EMT markers.

We investigated the role of OSM during the earliest stages of invasion and metastasis in an animal model. Our orthotopic injection studies have shown that OSM promotes maximum metastatic burden in lung and bone. Additionally, utilizing a modified human breast cancer cell line, the MDA-MB-231 cells, in an athymic, immunocompromised mouse, OSM applied directly to the tumor microenvironment increases the number of circulating tumor cells and number of metastasis to the lung. However, when we bypass the early stages of metastasis or those preceding colonization at a secondary metastatic site by implanting 4T1.2 mouse mammary tumor cells via intracardiac injection, there is no change in metastasis to the lung or survival time driven by OSM.

The difference between using a Balb/c mouse with mouse mammary tumor cells versus an athymic mouse with human breast cancer cells is not insignificant and one major difference between the two models. Application of human OSM directly to the tumor microenvironment did not affect primary tumor growth with the human MDA-MB-231 cells-DH3LN-luc., while loss of OSM from the mouse cells increased tumor growth. An explanation for this could be that full-length OSM may be less effective on growth inhibition in vivo due to its need for processing and its differential ability to signal when bound to proteins in the extracellular matrix of the tumor micron environment. Human OSM gene encodes a 252 amino acid (aa) polypeptide: the first 25 aa encode a signal sequence for secretion; the remaining 227 aa are the precursor protein named pro-OSM or full-length OSM. Cleavage of the c-terminis at a trypsin-like cleavage site yields the mature (aka active or truncated) 196 aa form. Both full-length and truncated OSM display similar receptor binding affinity, but full-length OSM was found to be 5 to 60-fold less effective on growth inhibition. Processing of OSM may regulate OSM activities in vivo. This differential growth effect between the two forms explains why peri-tumor injection of full-length OSM had no effect on primary tumor growth, but still maintained the functional properties of increased metastatic burden.

To explain the role of OSM in early stages of metastasis, we showed that 4T1.2 cells can detach, invade, and migrate in response to the cytokine. Epithelial cells, from which the majority of cancer cells such as 4T1.2 cells arise from, are not normally motile or invasive. In order for cancer cells to detach, invade, and become mobile through the ECM, they are thought to transform from an epithelial phenotype to a more mesenchymal phenotype. This phenomenon known as EMT involves reorganization of the cytoskeleton to allow cells to become mobile and thus migrate. As the cells become mesenchymal, they can produce proteinases such as matrix metalloproteinases to detach and invade into the ECM. Our results suggest that OSM's activity is primarily focused within the primary tumor and does not have an effect once the cells escape into the circulatory system. This is seen as OSM promotes tumor detachment and invasion in vitro, and metastasis in vivo when breast tumor cells are injected orthotopically.

It has been thought that tumor cell EMT, detachment, and invasion promote tumor cell propagation into the circulation and are thought to be precursors for intravasation and circulating tumor cells (CTC). Specifically, the cell's propensity to intravasate into circulation directly correlates to the level of CTC's. CTC's have also been linked clinically to enhanced metastatic burden in patients and a reduced 5-year survival rate. While the exact mechanisms that regulate CTC generation is unclear, factors such as transforming growth factor beta (TGF-beta), IL-6, and interleukin-8 may act as promoters of CTCs either by increasing tumor cell invasion, detachment, or EMT. Additionally, CTCs in general can tend to have a heterogeneous expression of genes and mixed epithelial/mesenchymal phenotypes, which complicate detection, and prognostic prediction. Results suggest that tumor cells that intravasate into circulation and become CTCs undergo EMT, invade through the ECM, and detach. Our data shows that OSM injection increases the number of CTCs in tumor bearing mice and this increase may be caused by OSM's effects on the early stages of metastases. Inflammatory cytokines such as IL-6, IL-17, and M-CSF at the site of the secondary lung metastasis, as well as in systemic circulation may foster their ability to proliferate, survive, and migrate. To date, it is not believed that investigation of OSM as a cellular cue in primary breast tumor environment promoting metastasis to the lung, despite several studies of the very closely related IL-6 cytokine.

OSM's pivotal role in the metastasis of primary cancers of the breast to sites such as bone and lung, and the known properties of OSM in the progression of inflammatory diseases, including arthritis and lung fibrosis give insight into the mechanisms that might drive OSM in the metastatic cascade. Tumors often appear to have chronic inflammation mediated by tumor-associated macrophages (TAMs). TAMs generally exhibit an M2 phenotype in which they produce growth factors and cytokines, promote ECM remodeling through the expression of proteases, and increase angiogenesis through the production of VEGF. Both tumor-infiltrating macrophages and neutrophils express and release OSM in response to breast carcinoma cells in vitro. OSM can also play a role in the switch from the M1 phenotype to M2 phenotype. OSM can also be both pro and anti-inflammatory in vivo but in the absence of tumor cells, OSM can trigger inflammatory cell recruitment when expressed in joints and lungs, and enhance dendritic cell homing to regional lymph nodes. In addition, OSM can promote changes in the ECM by increasing collagen deposition and increasing expression of proteases. In arthritic models, OSM can promote bone and cartilage production at higher levels than IL-6. Inflammatory cytokines such as IL-6, IL-17, and M-CSF can promote mammary tumor metastasis to the lung in the PyV MT mouse model when an arthritic disease state is induced with Type II collagen. In studies of skin inflammation, OSM can contribute to keratinocyte hyperplasia in psoriasis and dermatitis.

OSM can also promote inflammation and fibrosis in lung tissue and currently, and if chronic inflammation in the lung is present from either smoking or disease, breast cancer metastasis to the lung may be promoted. In both our in vivo models with either decreased OSM expression (4T1.2 mouse mammary tumor cells in a healthy Balb/c mouse) or application of OSM directly to the tumor microenvironment (MDA-MB-231 human breast cancer cells in an immunocompromised nude mouse), there is no increased basal inflammation in the lung microenvironment. Therefore, we can assume that inflammation is not the driving force for our observed differences in metastatic burden by OSM. However, OSM appears to be more important for initiating the early steps in the metastatic cascade preceding colonization in the lung.

OSM also increased IL-6 expression only in the ER-breast cancer cell lines MDA-MB231, MDA-MB-468, and 4T1.2 cells. IL-6 can increase breast cancer migration, invasion, and detachment. IL-6 can also induces EMT, and high serum IL-6 levels can be associated with poor prognosis in breast cancer patients. OSM's effect on tumor progression may also be magnified by the induction of IL-6, as IL-6 can also promote further induction of IL-6 production in a feed forward system.

In the bone microenvironment, OSM expression by metastatic cells can directly interfere with the homeostasis of the osteogenic cells, and lead to increased osteolysis, suggesting a role for OSM in the metastatic niche during later stages of metastasis. Returning to prostate cancer, the inventors now describe their further findings in relation to this tumor. FIG. 10 shows a schematic of a mechanism by which OSM is presumed to promote the metastasis and progression of prostate tumors. OSM produced by prostate tumor cells promotes the expression of proteases, such as MMPs and cathepsins that in turn stimulate EMT, detachment, and invasiveness of tumor cells. In addition, OSM can induce tumor cell expression of proangiogenic factors such as VEGF and u-PA that promote angiogenesis and metastasis.

OSM can play a role in the initial stages of prostate cancer metastasis. DU-145 prostate cancer cells can undergo increased proliferation, EMT, detachment, and invasive potential in response to OSM treatment (see FIGS. 11-14). Initial results suggest that OSM's effects on proliferation and cell detachment work through a STAT3 signaling mechanism, but that its effects on invasive potential may work through a different pathway. In vitro studies indicate that OSM can induce vascular endothelial growth factor (VEGF) and urokinase-type plasminogen activator (u-PA) in prostate cancer cells.

Given the role of OSM in the metastases of prostate cancer and other types of cancer, we investigated various small molecule inhibitors of OSM. It is our assumption that increased inhibition of OSM may be correlated with a decreased degree of cancer metastases, particularly prostate cancer metastases. Several classes of small molecules were investigated in this regard and are summarized in Table 1, Formulas 1-10 below along with their in silico predicted binding constants for OSM.

Methods for inhibiting OSM can include exposing OSM or a cell line expressing OSM to a small molecule inhibitor of OSM, including those of Formula 1-10 or various derivatives thereof.

Methods for treating cancer can include administering a pharmaceutical composition containing a small molecule OSM inhibitor to a patient with prostate cancer. Administration can be orally, parenterally, rectally, topically, intravenously, and the like under a suitable dosing schedule compatible with the metabolic clearance of the active compound. The active compound is included in a pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the patient being treated. The therapeutically effective concentration may be determined empirically by testing the compounds in in vitro and in vivo systems described herein and then extrapolated therefrom for dosages for humans. The concentration of active compound in the pharmaceutical composition will depend on absorption, inactivation and excretion rates of the active compound, the physicochemical characteristics of the compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Patent publications cited herein and the materials for which they are cited are specifically incorporated by reference. To facilitate a better understanding of the embodiments of the present disclosure, the following examples are given. In no way should the following examples be read to limit, or to define, the scope of the invention.

EXAMPLES

Tissue Microarrays:

Breast tissue was obtained from paraffin block archives at the Department of Pathology, Mercy Medical Center, Nampa, ID and removed of patient identity as per IRB guidelines. Three tissue microarrays (TMA) of 1 mm thickness and totaling 72 patients were made using a Quick-Ray, an instrument used for boring tissue from a paraffin block (Woo-Ri Medic, Kent, Wash.). Two blocks consisted of tissues from 54 breast cancer patients (32 adjacent normal, 9 DCIS patients, 54 IDC) without metastasis and included three primary tumor cores and one adjacent normal core for each case. The third block included samples from a total of 18 breast cancer patients (18 adjacent normal, 3 DCIS, 18 IDC and 16 metastatic) with lymph node metastasis and contained three primary tumor cores, two metastatic cores and one adjacent normal tissue core per case. The TMAs included a row of control tissues including spleen, lung, placenta, salivary gland, liver and brain. Spleen and salivary gland served as positive controls for OSM staining.

Immunohistochemistry:

The TMAs were stained for oncostatin M using the Histostain Kit (Cat #95-9843; Invitrogen, Carlsbad, Calif.) per manufacturer's instructions. The TMAs were deparafinized using Histosol (National Diagnostics, Atlanta, Ga.) and stained overnight with 1:400 dilution of rabbit anti-human OSM primary antibody (Cat #sc-129; Santa Cruz Biotechnology, Santa Cruz, Calif.) and 1 hour with 1:1000 goat-anti rabbit IgG-AP secondary antibody. TMAs stained with secondary antibody alone served as the negative control, and spleen and salivary gland served as positive controls for OSM staining. The specificity of the α-OSM antibody was tested by treating tissue sections with 10-times the amount of OSM blocking peptide (Santa Cruz Biotechnologies, Santa Cruz, Calif.) and incubating overnight at 4° C. The mixture was then diluted to the required concentration and immunohistochemistry was performed as above.

The TMAs were analyzed for OSM expression and the intensity of OSM staining in the ductal epithelium, stroma, and blood vessels of adjacent normal and cancerous tissue was graded as follows: 0=No staining; 1=Light staining; 2=Medium staining; 3=Dark staining. In order to confirm reproducibility of the results, the pathologist reread 10 TMA cores that were chosen randomly, and his observations were consistent with the previous results. In cases where a single core had both cancerous and normal tissue, the OSM expression data in the cancerous part was combined with other cancerous tissues and the expression in the normal part was combined with other adjacent normal tissues for statistical analysis. Also in these cases, stroma, and blood vessels were considered as cancerous.

The TMAs were also stained with CD15 antibody that specifically stains human neutrophils and CD68 antibody that specifically stains human macrophages. Tissues were deparafinized, hydrated and treated with 3% hydrogen peroxide solution for 10 min, treated with a target antigen retrieval solution in a pressure cooker for 15 min, rinsed, and incubated with the primary antibody (CD15 or CD68) for 30 min. This was followed by secondary antibody staining for 15 min, DAB staining for 10 min and hematoxylin staining for 10 min. The above staining procedure was conducted at the Mercy Medical Center, Nampa, ID using an autostainer (DAKO, DC3400-7218-03). By comparing the macrophage or neutrophil staining to the corresponding OSM staining, we visually assessed if the macrophages or neutrophils expressed OSM.

Statistical Analysis:

Assessments from multiple cores for each patient were averaged for each cell tissue type (ductal epithelial, vessel, stroma) and stage of malignancy (normal, DCIS, IDC, metastatic) that was present in the core. The four stages were statistically compared among ductal tissues. For vessels and stroma, the stage was characterized either as cancerous or non-cancerous because the three cancerous stages (DCIS, IDC, metastatic) could not be ascertained for these tissues. The OSM staining intensity was analyzed as a mixed model to accommodate repeated observations on each patient. These repeated observations were assumed to have non-negligible correlation and were modeled under standard repeated measures variance-covariance assumptions. Stage was treated as a fixed effect. Additionally, statistical models considering patient prognostic markers were evaluated. These models included the stage and the prognostic marker, with or without an interaction; the model with the lowest AIC_(c) was selected to determine whether the prognostic factor was associated with OSM staining. These prognostic factors considered were age, tumor size, lymph node status, angiolymphatic invasion, tumor grade, tumor type, histologic grade, nuclear atypia, margin status, mitotic rate, Her2/neu expression, progesterone and estrogen receptor. Initial assessments indicated that OSM staining intensity did not differ significantly between the two groups of patients (patients with and without lymph node metastasis) so patient group was not included as an analysis factor in the study. All models were assessed for adequacy by residual analysis, a concern here because of the bounds on OSM staining intensity (0-3) and our specific interest in changes in mean staining intensities. No predicted values exceeded the possible observational boundaries and residual patterns were acceptable despite the categorical nature of the data collection. All analyses were conducted using SAS version 9.1.3 (SAS 2004).

Cell Lines and Culture Conditions:

4T1.2 cells were cultured in MEMα media supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, and 100 units/ml each of penicillin and streptomycin, and passaged for no more than 6 months. MDA-MB-231 D3H2LN luc2 cells (Caliper Life Sciences) were cultured in RMPI media supplemented with 10% FBS and 100 units/ml of penicillin and streptomycin. Cells were maintained at 37° C., 5% carbon dioxide, and 95% humidity. All media and supplements were obtained from Hyclone (Logan, Utah). 4T1.2 mouse mammary cell lines were generated in-house.

Plasmid Construct Design and Cell Transfections:

To create OSM knockdown vectors, OSM shRNA and a LacZ shRNA sequences were cloned into the pSilencer 4.1 plasmid (Ambion, Austin, Tex.). Briefly, 4T1.2 cells were transfected with the pSilencer 4.1 constructs containing the one of the two mOSM shRNAs or a LacZ control shRNA using lipofectamine LTX (Invitrogen Carlsbad, Calif.) reagent, as per manufacturer instructions. Stably transfected cell lines were grown in the presence of 0.3 mg/mL of the neomycin analogue G418 (Sigma Aldrich). All established cell lines were checked for OSM expression by ELISA.

Animals and Tumor Cell Injections:

For syngeneic studies, six-week-old female Balb/c mice were obtained from the National Cancer Institute's Animal Production Facility (Frederick, Md.). For orthotopic injections, each mouse was anesthetized by i.p. injection of 6.25 mg/kg of sodium pentobarbital or with 2.5% isoflurane and 1.0×10⁵ cells diluted in 10 μL of PBS containing 10% medium were injected into the 4^(th) mammary fat pad. For tumor resection, mammary tumors were surgically excised 14 days after orthotopic injections. All animal studies were conducted in accordance with the protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the Boise VA Medical Center, Washington University School of Medicine in St. Louis, Mo., or the Peter MacCallum Cancer Centre in Melbourne, Australia. Starting at 2 weeks post-injection, tumor length and width were measured by mechanical calipers 3 times a week and tumor volume was extrapolated using the following equation (tumor volume=(length×width^2)/2). “Survival endpoint” was defined by the IACUC as tumor size greater than 20 mm in diameter, 10% or more weight loss, and/or appearance of cachexia.

For xenograft models, six-week-old female nude mice were obtained from the National Cancer Institute's Animal Production Facility (Frederick, Md.). Non-surgical orthotopic injections were performed using 2.0×10⁶ cells diluted in 50 μL of PBS containing 10% medium. When the tumors became palpable, mice were randomized into groups and began receiving per-tumoral injections. For peri-tumoral injections, either 50 μL PBS or 1 μg recombinant full length human OSM (Peprotech) diluted in 50 μL PBS was injected into the area surrounding the tumor three times per week until the end point of the experiment.

Quantitative PCR (qPCR):

For quantitative analysis of lung metastases, lungs dissected from mice bearing mammary tumor were snap-frozen in liquid nitrogen and pulverized into a fine powder. DNA was extracted using an STE buffer containing 20 μl/ml of proteinase K and purified by two phenol/chloroform (1:1 v/v) extractions followed by ethanol precipitation. The ratio of cancer cells to normal cells was quantified by measuring the neomycin resistance gene (neon) DNA levels versus the vimentin DNA loading control. Taqman PCR was performed on an Applied Biosystems 7500 real-time thermocycler. The cycling conditions were run as follows: 50° C. for 5 minutes, 95° C. for 2 minutes, then 40 cycles of 95° C. for 1 minute and 60° C. for 45 seconds. Fluorescence was measured every cycle after the annealing step and threshold cycle number (CO values were calculated. The data was analyzed using the comparative DCt method.

Detection of CTCs:

Detection of human circulating tumor cells (CTCs) in mouse blood was performed. Human DNA standard curve was prepared by adding a specified number of human MDA-MB-231 cells into mouse blood and the DNA isolated for use in the qPCR reactions. Whole DNA was isolated from 100 μl of whole blood collected from mice at the end of the experiment. DNA was isolated using DNeasy Blood & Tissue kit (Quiagen Cat#) using the manufacturer's standard instructions. DNA concentrations were normalized between each sample and 4.5 ng of DNA was added to each 25 μl qPCR reaction. qPCR reaction mixture was obtained from the GoTaq qPCR Master Mix (Promega, Cat#TM318, Madison Wis.), and reaction mixtures were prepared in accordance with manufacturer recommendations. 0.125 μl of 100 μM primers for human Alu fragment, and for GAPDH was added to each reaction. The primer sequences used for Alu was (s:CACCTGTAATCCCAGCACTTT a:CCCAGGCTRGGAGTCGCAGT) and for

GAPDH the sequence used was (s: ATGACATCAAGAAGGTGGTG; a: CATACCAGGAAATGAGCTTG). The qPCR reaction was done with SYBR green chemistry using a CXR reference dye and ran on an Applied Biosystems AB7300 real-time thermocycler. Reaction conditions were: 50° C. for 2 minutes, 95° C. for 3 minutes and 40 cycles of: (95° C. 00:15, 60° C. 00:30, 72° C. 00:30) and fluorescence measurements were taken during the annealing temperature stage (60° C.). cT values were determined and the final results were normalized to GAPDH signal levels.

In-Vivo Magnetic Resonance Imaging:

Respiratory-gated, spin-echo MR images of mice were collected in an Oxford Instruments (Oxford, UK) 4.7 tesla, 40-cm bore magnet. The magnet was equipped with Agilent/Magnex (Yarnton, UK) actively shielded, high-performance (21-cm inner diameter, ˜30 G/cm, ˜200 ms rise time) gradient coils and International Electric Company (Helsinki, Finland) gradient power amplifiers and interfaced with an Agilent/Varian NMR Systems (Santa Clara, Calif.) DirectDrive™ console. All data were collected using a Stark Contrast (Erlangen, Germany) 2.5 cm birdcage if coil. Prior to the imaging experiments, mice were anesthetized with isoflurane and were maintained on isoflurane/O₂ (1-1.5% v/v) throughout data collection. Animal core body temperature was maintained at 37±1° C. by circulation of warm air through the bore of the magnet. During the imaging experiments, the respiration rates for all mice were regular and ˜2 sec⁻¹. Synchronization of MR data collection with animal respiration was achieved with a respiratory-gating unit and all images were collected during post-expiratory periods. Imaging parameters are TR=3 s, TE=20 ms, FOV=2.5 cm², Data matrix=128×128; slice thickness=0.5 mm; number of averages (NEX)=4.

In Vivo Bioluminescence Imaging (BLI) and Tumor Progression:

BLI of live animals was initiated at 13 days after cell line injection and performed weekly. Three to five mice were imaged at one time. Ex vivo organs were also imaged using BLI. Both procedures follow our previously described protocols.

Histology:

To verify lung metastasis, lungs from each experimental group (4T1.2-LacZ, n=2; 4T1.2-shOSM2, n=2; and 4T1.2-shOSM1, n=1) were placed in ultralight fixative (Ultralight Histology, Nampa, Id.) paraffin embedded, and sectioned (Bi-Biomics, Nampa, Id.). For each spine, four 1 μm sections were collected 10 μm apart in the lumbar region and H&E stained.

IL-6 ELISA:

1×10⁵T47D, MDA-MB-231, MCF7, MDA-MB-468, or 4T1.2 cells were plated in multi-well plates in the presence or absence of OSM for 47 hours. Conditioned media was collected, diluted 1:5 and an IL-6 ELISA was performed as according to the manufacturer's recommended instructions.

3 mm cubes were excised from tumors dissected from mice injected with MDA-MB-231 cells. The tissue was homogenized in lysis buffer (Pathscan lysis buffer, Cell Signaling) using a pestle. Cell lysates were then diluted 1:5 and IL-6 levels in the lysates were analyzed by ELISA as discussed above.

Statistical Analysis.

Data are displayed as mean±standard error of the mean (SEM). Data were analyzed using an unpaired student's t-test or analysis of variance (ANOVA) with Tukey's multiple comparison post-hoc test where appropriate, using Prism GraphPad 5.0b software (GraphPad Software Inc., San Diego, Calif.). Survival data were analyzed using the Log-rank (Mantel-Cox) test. In the analyzed data, asterisks denote *p<0.05, **p<0.01, or ***p<0.001.

Example 1: Oncostatin M is Highly Expressed in Early Stages of Ductal Carcinoma of the Breast

The expression of OSM in a series of TMA breast samples was analyzed by immunohistochemistry (IHC). Treatment of OSM antibody with 10-fold excess OSM blocking peptide followed by IHC resulted in no positive staining, indicating that the antibody is specific to OSM (data not shown).

Three TMAs containing samples from a total of 72 patients were employed for this study. Of these, 54 patients were from the non-metastatic group and 18 were from the metastatic group. The metastatic group contained samples from patients diagnosed with metastasis of IDC to lymph nodes. All patients in this study were diagnosed with IDC. A total of 12 patients also had DCIS. In addition, the TMAs contained adjacent normal tissues from a total of 50 patents (FIG. 1A).

FIG. 1A shows how the 72 patients provided data for the statistical analysis of OSM expression. All of the 72 samples with IDC expressed OSM while 46 of the 50 adjacent normal ductal tissues were positive for OSM expression. OSM staining intensity differed significantly among the four stages (F_(3,278)=10.0, p<0.001). Adjacent normal breast tissue mean staining intensity (1.33) was significantly less than that of DCIS (2.00) and IDC (1.66) (FIG. 1A). In these tissues, OSM expression was uniformly concentrated in the cytoplasm of the ductal epithelial cells with some expression in the stroma and blood vessels (discussed in the following sections). Additionally, OSM expression in the metastatic tissue (1.24) was lower than that of IDC and DCIS, white it was statistically similar to adjacent normal breast tissue. Ductal epithelial cells of cancerous breast tissue express high levels of the OSMRβ and pg130 subunits of the OSM receptor; therefore, OSM expression by the ductal epithelial cells indicates an autocrine mechanism for OSM function in breast cancer progression.

Our finding that OSM expression is higher in earlier stages of breast cancer than in metastatic tissue suggests that OSM may promote the invasive capacity of breast tumors in vivo and its role may be less significant once the tumor has metastasized to distant tissues. It is believed that OSM-promoted cell detachment and invasive capacity is through the induction of several tumor promoting factors such as COX-2, MMPs, cathepsins-D and -L, basic-fibroblast growth factor (bFGF), and VEGF. This pattern of OSM expression is also consistent with an EMT (epithelial to mesenchymal transition), which has previously been suggested as a role for OSM. Since metastatic tissue contains tumor cells that have already been altered and need to resume proliferation, OSM may no longer be required and hence may be down regulated. Recent findings have shown that OSM is not highly expressed in pure, isolated cases of in situ ductal carcinoma, which usually does not have invasive capacity. OSM is also highly expressed in mature keratocanthoma that has a tendency to involute and infiltrate breast tumors.

Example 2: OSM Promotes Mammary Tumor Metastasis to Lung

To examine whether OSM is required for mammary tumor metastasis to lung, we undertook stable knockdown of OSM expression. Two independent OSM shRNA sequences were cloned into the pSilencer4.1 vector and transfected into 4T1.2 mouse mammary tumor cells (T1.2-shOSM1 and 4T1.2-shOSM2) using a procedure known to result in a 3 to 12-fold reduction in OSM expression. To test the effects of OSM on mammary tumor metastasis in vivo, control 4T1.2-LacZ, 4T1.2-shOSM1, and 4T1.2-shOSM2 cells were injected orthotopically into the mammary fat pads of Balb/c mice. Low levels of secreted OSM in the 4T1.2-shOSM2 cells were shown by our lab to result in increased primary tumor growth. However, injection of 4T1.2-shOSM1 cells, which displayed a modest decrease in tumor cell-secreted OSM, did not affect tumor growth in vivo.

Metastasis to lung in mice injected with control 4T1.2-LacZ, 4T1.2-shOSM1, and 4T1.2-shOSM2 cells were quantified by qPCR. Mean lung metastatic burden in lung was 10-fold lower in mice that received 4T1.2-shOSM1 cells and 5-fold lower in mice injected with 4T1.2-shOSM2 cells, compared to 4T1.2-LacZ control cells (FIG. 1A). Histological evaluation of lung by H & E staining revealed the presence of large metastases in mice injected with 4T1.2-LacZ control cells but many fewer and smaller metastases in mice injected with 4T1.2-shOSM1 and 4T1.2-shOSM2 cells (FIG. 1A). Additional histology performed on tissues from mice injected with parental 4T1.2 cells, using an anti-mouse OSM antibody, showed strong OSM expression in the primary mammary tumor as well as some background expression in the normal breast connective tissue (FIG. 1B). Very high OSM expression was shown at the leading edge of the primary tumor metastasis, in closest proximity to the breast stroma (FIG. 1B). In total, these results suggest that OSM is necessary for spontaneous mammary tumor metastasis to lung and may be aided by interactions with the lung tissue inflammatory microenvironment.

Example 3: OSM Expression Increases the Number and Volume of Lung Metastases In Vivo

To more specifically characterize and quantify the progression of lung metastases seen in vivo after injection of parental 4T1.2, control 4T1.2-LacZ, and 4T1.2-shOSM2 cells, in vivo magnetic resonance imaging (MRI) experiments were performed. Respiratory-gated spin-echo images, with coronal orientation, were collected with sufficient slices (e.g., 21 slices, 0.5 mm thickness) to completely cover the lungs of each animal. Mice were imaged at early (days 20-21), mid (days 25-26), and late (days 29-30) stages of in vivo metastasis (FIG. 3A). For all three cell types, MRI spectra showed essentially no detectable metastasis at the early stages. At mid and late stages, however, readily identifiable metastases were observed in lung images. Lung tumors were manually segmented with IMAGE J (rsbweb.nih.gov/ij), and the number and volume of all metastatic tumors were measured and recorded, on an animal-by-animal basis. As illustrated in FIG. 2B, the number of metastases was reduced by more than 50% in mice injected with 4T1.2-shOSM2 cells compared to control 4T1.2-LacZ control cells at both mid and late stages of metastasis. Additionally, the average metastasis volume was significantly decreased by 50 to 80% in 4T1.2-shOSM2 cells compared to 4T1.2-LacZ control or parental 4T1.2 cells, respectively, at mid and late stages of metastasis. Thus, the in vivo MRI imaging suggested that OSM is a potent inducer of the metastatic cascade that results in lung metastases originating from a primary mammary tumor.

Example 4: Lack of Mammary Tumor Cell-Produced OSM Increases Survival from Spontaneous Metastasis Via Orthotopic Injection but not Via Intracardiac Injection In Vivo

To determine the influence of decreased OSM expression on metastasis independent from its effects on primary tumor cell proliferation, we utilized a tumor resection model. Orthotopic mammary fat pad injections were performed using control 4T1.2-LacZ cells, 4T1.2-shOSM1, and 4T1.2-shOSM2 cells, primary tumors were resected at day 14 (FIG. 4A), and mice were monitored until endpoint criteria were met (see above). The mean survival time of the mice that received 4T1.2-shOSM1 and 4T1.2-shOSM2 cell injections significantly increased by a mean of 37 and 42 days and a maximum of 44 and 72 days, respectively, compared to 4T1.2-LacZ that survived a mean of 32 days and maximum of 36 days. These results suggest that following primary mammary tumor resection, decreased OSM expression in primary tumor cells leads to a delay in metastasis and increased survival.

In order to determine if OSM expression is most important in the early or late stage of metastasis, we injected the mammary tumor cells directly into the systemic circulatory system via the left ventricle of the heart. Intracardiac injections of control 4T1.2-LacZ and 4T1.2-shOSM2 cells did not result in significant changes in survival time or the number of cells that colonized in the lungs (FIG. 4B). This indicates that OSM expression in tumor cells affects the early stages of metastasis that proceed their successful survival in circulating blood more significantly than later stages of metastasis involving colonization, survival, and proliferation at distant metastatic sites such as lung.

Example 5: OSM Affects In Vivo Using Human MDA-MB-231 D3H2LN Cells

To determine the influence of OSM in human breast cancer, we used a xenograft model. MDA-MB-231 D3H2LN luc2 cells were injected into the fourth mammary fat pads of female nude mice. After the tumors were palpable, OSM (1 μg) or PBS were injected peri-tumorally 3 times per week (FIG. 6A), and mice were monitored until the end-point criteria were met. Tumor size was measured using calipers three times per week for the duration of the experiment and expressed as tumor volume (mm³)=(length×width). Tumor volume did not differ between the groups (FIG. 6B). Next, BLI intensity of the cells was assessed in vivo. The BLI intensities of the tumors from both groups were similar with variations in intensities in both groups (FIG. 6C). A few mice in both groups had lower BLI intensities due to tumor necrosis.

Example 6: OSM Increases the Metastatic Volume within the Lungs which Correlates with an Increase in Circulating Tumor Cells

Ex vivo analysis of the lungs was performed. Mice receiving peri-tumoral OSM injections showed larger metastatic volume while the mice receiving PBS injections showed a few micro-metastases within the lungs (FIG. 6C). Interestingly, lungs of two of the OSM injected mice were imaged on an order of 10⁶ photons/sec/cm² (FIG. 6C; OSM group, right panel) while the other lungs were imaged on an order of 10⁴ photons/sec/cm² (FIG. 6C; PBS group and OSM group, left panel). Next, quantification of the BLI intensities of the lungs was performed. Results showed that lungs extracted from the OSM injected group were two orders of magnitude (10²) higher than the PBS injected group.

Our studies on detecting CTCs involve the usage of the Alu transposon repeats for detecting human cells in mouse blood, and with colony forming assays that detects all transformed cells in the blood. We verified this by measuring the number of circulating tumor cells (CTCs) in mice orthotopically injected with mammary tumor cells. In order to detect circulating tumor cells in the mouse circulatory system, DNA was isolated from mouse blood, and human alu fragment concentrations were determined in the blood by qPCR. In our xenograft model, we injected human MDA-MB-231 cells into the 4^(th) mammary fatpad and any circulating tumor cells contain multiple copies of human Alu fragments. In animals that received rhOSM injections, there was a 3.5 fold increase in the number of circulating tumor cells per 100 μl of mouse blood over animals that did not receive any OSM injections.

Example 7: OSM Promotes IL-6 Expression in ER Negative Cell Lines

OSM induced IL-6 expression was studied on various cell lines including two ER+ cell lines, T47D and MCF7, and three ER− cell lines MDA-MB-468, MDA-MB-231, and 4T1.2 cells. rhOSM was used for the four human cell lines at a concentration of 25 ηg/ml while rmOSM was used for the 4T1.2 cells at a concentration of 25 ηg/ml. The cells were incubated in OSM for a total of 48 hours and IL-6 levels in the conditioned media was assessed by ELISA. OSM did not induce IL-6 on the ER+MCF7 or T47D cells, while in MDA-MB-468 cells, OSM induced IL-6 approximately 5-fold, while in MDA-MB-231 cells IL-6 levels increased by approximately 4-fold. In the 4T1.2 mouse mammary cancer cells, OSM induced IL-6 by approximately 4-fold (FIG. 7). To test if OSM induced IL-6 in vivo, tumors from the MDA-MB-231 injected mice were lysed, homogenized, and the IL-6 levels were analyzed by ELISA.

Example 8: OSM Promotes Metastases to the Spleen and Liver in a Mouse Model

As shown in FIG. 9, 4T1.2 metastases were observed in the spleen and liver in a mouse model.

Example 9: Proliferation and Detachment of Prostate Cancer Cells

Prostate cancer cell lines DU-145 and PC-3 were plated in triplicate in complete RPMI media at a cell density of 1,000 cells/ml and allowed to adhere overnight. Cells were treated the next day with OSM at a concentration of 17.5 ηg/ml (untreated cells were used as a control). Both detached cells and total cells were counted on days 1, 3, 5, 7, and 9. Detached cells were collected, stained with trypan blue and viable cells were counted using a hemocytometer. Adherent cells were trypsinized, stained with trypan blue and viable cells were counted on a hemocytometer. To look at the effects of OSM on prostate cancer cell proliferation, the number of viable detached cells and adherent cells were added together to determine the total number of cells.

The addition of OSM significantly increased proliferation (FIG. 11) (P=0.0247) and cell detachment (FIG. 12) (P=<0.0001) in DU-145 cells, but not in STAT3 PC-3 cells. These results suggest that OSM mediates its effect on proliferation and detachment through a STAT3 signaling pathway.

The Epithelial-Mesenchymal Transition (EMT) was also measured. During the proliferation and detachment assays detailed above, micrographs of the DU-145 cells were taken at day 5 before cells were collected and counted. At day 5, untreated DU-145 cells exhibit an epithelial morphology and were packed closely together in a round colony formation (FIG. 13). However, the OSM-treated DU-145 cells showed a more mesenchymal morphology, were more fibroblastic in shape, and spread further apart from each other.

Invasion potential was also measured. OSM increased the invasion potential of both DU-145 and PC-3 cell lines (FIG. 14). Twenty three percent of treated DU-145 cells showed an invasive potential as compared to 15% of untreated DU-145 cells, and 21% of treated PC-3 cells showed an invasive potential as compared to 14% of untreated PC-3 cells. PC-3 cells pretreated with OSM for 72 hours had a 4-fold increase in invasive potential, as compared to untreated PC-3 see FIG. 15. These results suggest that the increased invasive potential mediated by OSM uses a signaling pathway distinct from that of proliferation and cell detachment and one that does not use STAT3.

Example 10

Our preliminary calculations show that there are three potential SMI binding sites on the OSM surface. A structural alignment of OSM and LIF-LIFR complex (PDB ID: 2Q7N) indicates that site 1 is putatively close to OSM-OSMR binding interface, site 2 is located at the waist region of OSM, and site 3 is at the far end from the binding interface. SMIs that bind to site 1 are expected to directly interrupt OSM binding to OSM receptor. SMIs that bind to site 2 or site 3 may also interfere with OSM-OSM receptor binding through allosteric effects. Structures identified by AutoLigand will be used to query compounds from an in-house database using the OpenEye suite program (41). AutoDock Vina and AutoDock 4.2 programs will be used to rank drug-like compounds based on their predicted binding free energy potential to binding sites.

Table 2 along with CB_CL111696, CB_CL19531, and CB_CL81250 from Table 1 show the top candidates obtained from our initial preliminary virtual screening for interactions at Site 1 of three databases containing ˜345,000 compounds. We plan to screen a total of 2.5 million compounds from multiple select databases. All compounds with predicted binding constants in the <10 μM range and/or binding free energies higher than −5.0 kcal/mol will advance.

Off-target effects will be assessed by computational prediction of lead OSM-SMI for their specificity to OSM, as compared to other IL-6 cytokines including LIF, interleukin-11 (IL-11), ciliary neurotropic factor (CNTF), and cardiotrophin-1 (CT-1). Compounds with favorable predicted binding constants and no predicted off-target effects will also be assessed using the SciFinder program to identify related or “like” compounds. Chemicals showing greater than 70% relatedness and not identified in our in silico screening of 2.5 million compounds will feed back into the initial in silico screening. Overall, the top 100 compounds that exhibit substantial selectivity and specificity will be considered viable drug leads and undergo in vitro testing.

Next, we will evaluate the in vitro performance of the top OSM-SMI leads obtained from in silico screening. This involves testing OSM-SMIs for signal inhibition and in vitro efficacy, respectively.

All human breast carcinoma cell lines used in this aim will be purchased from the American Type Culture Collection (ATCC) or Caliper Life Sciences, and the growth of frozen cell aliquots will be initiated on a periodic basis to remove the possibility of cross-cell contamination. The cell lines will be regularly tested for mycoplasma contamination by both DAPI staining and PCR. We will use four invasive ductal carcinoma cell lines [T47D, MCF7, MDA-MB-231 and MDA-MB-468]. These include the less aggressive, estrogen receptor-positive (ER+), progesterone receptor positive (PR+), HER2-, luminal T47D and MCF7-luc cell lines, as well as the triple negative breast cancer (TNBC) basal-like cell line, MDA-MB-231-LN-luc, that is metastatic in orthotopic xenografts and the less metastatic TNBC cell line MDA-MB-468. All cell lines express OSMRb, LIFRb, and gp130, as well as various levels of OSM, by RT-PCR (data not shown).

Next an enzyme-linked immunosorbent assay (ELISA) for analyzing initial OSM-induced phosphorylation of STAT3 on Tyr-705 (pSTAT3) will be employed for the initial screen. T47D, MCF7, and MDA-MB-231 human breast cancer cells induced pSTAT3 upon stimulation with OSM (25 ηg/ml) for 30 minutes. The ability of the top 100 OSM-SMIs to inhibit OSM-OSMR interactions that result in expression of pSTAT3 will be evaluated by this assay and cells will be pretreated with the OSM-SMIs for 2 hours prior to the addition of OSM. As positive controls, neutralizing antibodies to human OSM or human gp130 will establish baseline pSTAT3 levels in the ELISA assay (FIG. 16A).

Using this pSTAT ELISA test, we preliminary screened 16 identified lead compounds (Table 2) in T47D and MDA-MB-231 breast cancer cells (FIG. 8B, C) and Dul45 human prostate cancer cells (FIG. 8D) and demonstrated a significant inhibition of pSTAT3 with OSM-SMI-8 after treatment with a reduced level of OSM (5 ng/ml). Actual physiological levels of OSM may be much lower than the nanogram levels used here. Healthy humans have been shown to have OSM serum levels of 6-13 pg/ml, cancer patients with hepatocellular carcinoma have serum levels of 29-121 pg/ml, and mice with MDA-MB-231 mammary tumors contain 6 to 85 pg/ml in their serum (data not shown). Therefore, testing inhibitors using lower concentrations of OSM may better allow for the detection of Effects at physiologically relevant concentrations.

Additionally, a functional dose response curve for OSM-SMI activity will be generated through 2 log units of concentration of compounds and used to establish the dynamic range of OSM-SMI activity. This will be used to determine the half maximal inhibitory concentration (IC₅₀) as well as the minimum effective concentration (C_(eff)) for each compound. In preliminary data, OSM-SMI-8 demonstrated an IC₅₀ of 531 ηM when tested in MDA-MB-231 cells after treatment with OSM (5 ηg/ml) for 30 minutes (FIG. 9A).

The top 20 positive OSM-SMI compounds (IC₅₀<5 μM) will be assessed for thorough blocking of OSM signaling. OSM-SMIs will be introduced to T47D, MCF7, MDA-MB-231, and MDA-MB-468 cells at the determined C_(eff) and tested for inhibition of pSTAT3, pJNK, pERK, and pAKT by Western blot analysis. In preliminary data, OSM-SMI-8, -10 and -11 (5 μM) were tested for suppression of downstream signaling by Western blot analysis of two independent sets of MDA-MB-231 cell lysates (FIG. 17B). This experiment confirmed the ELISA test for OSM-SMI-8 suppression of pSTAT3, as well as demonstrating inhibition of pJNK, pERK, and pAKT. OSM-SMI-10 and -11 also inhibited signaling to various extents (FIG. 9B). This data suggests that the in silico screening is successful in identifying OSM-SMIs that can block OSM signaling.

OSM-SMIs will also be biologically evaluated for off-target effects by their specificity for OSM and not other IL-6 cytokines. The four human breast cancer cell lines [T47D, MCF7, MDA-MB-231, and MDA-MB-468] will be pretreated with each OSM-SMI for 2 hours and then treated with IL-6, LIF, IL-11, CNTF, or CT-1 (5 μM) for 30 minutes. Cell lysates will be evaluated by Western blot analysis for pSTAT3, pJNK, pERK, and pAKT.

The top 10 candidates will be evaluated for their ability to inhibit tumor cell proliferation, cell detachment, vascular endothelial growth factor (VEGF) secretion, and invasive capacity of the above mentioned cell lines by addition of OSM-SMIs to cell culture media at C_(eff). These experiments will proceed in a fashion similar to our previously published work analyzing human and mouse mammary carcinoma cells in vitro. Briefly, proliferation will be measured by cell counting after pretreatment of cells with each OSM-SMI and then treatment with OSM for 2, 4, and 6 days, and percent-detached cells will be determined over time by counting the number of non-adherent cells and dividing this number by the total number of cells. To examine OSM-induced invasive potential in vitro, Matrigel invasion assays (BD Biosciences) will be performed as described previously. VEGF secretion will be assessed in the conditioned media of cells pretreated with the OSM-SMIs and then treated with OSM for 48 hours.

The steady state drug dissociation constants, K_(D), of the candidate OSM-SMIs will be determined. Binding studies will be performed in the presence of OSM using LC-MS technique incorporating a C18 reverse phase HPLC column to effect separation and detection of the unbound OSM-SMI fraction.

To assess cellular toxicity of the top 5 OSM-SMIs against human breast cancer cells, dose-response curves for cell viability will be established for the above mentioned cell lines, as well as normal human mammary epithelial cells (HMECs), using CellTiter-Glo (Promega) and LC₅₀/LC₉₀ values established. To evaluate global toxicity and organ-specific toxic effects, the integrated discrete multiple organ cell culture (IdMOC) system developed by Li will be used. Compounds with a 100-fold or greater normal/tumor cell toxicity ratio and an IdMOC cell survival rate above 90% will be advanced for in vivo testing.

Next, we will perform in vivo testing of candidate OSM-SMIs with the explicit purpose of identifying one or more compounds that can inhibit metastasis in a mouse model of human breast cancer.

The top 3 to 5 compounds will be pre-screened for acute toxicity. Briefly, 50 mg/kg of each compound will be dissolved in vehicle [dimethyl acetamide (DMA)/PEG-400/PBS] and injected intravenously into the tail vein of three mice. Mice will be observed for signs of acute toxicity over 48 hours. Up to three OSM-SMIs exhibiting no toxicity will enter the pre-clinical studies.

In vivo studies will be performed using the MDA-MB-231-LN-luc orthotopic xenograft mouse model of breast cancer. Female athymic mice will receive 10⁶ tumor cells in 10 μl PBS injected into the 4^(th) mammary fat pad at day zero, and randomized into different groups. Tumors will be resected when they reach 5 mm in diameter. After tumor resection, animals will receive candidate drugs at three different concentrations in vehicle by intraperitoneal (i.p.) injections three times per week for the life of the animal. Conservative estimates from our preliminary data on OSM knockdown indicate that a group size of n=20 mice will have 80% power at α=0.05 to detect differences in survival of 10 days and >80% power to detect difference in tumor growth and metastasis of at least 20%.

Whole blood will be analyzed for complete blood counts (CBC), and serum will be analyzed for OSM and IL-6 levels. CTCs, tumor growth, and metastasis will be measured. End point metastases will be evaluated by ex vivo BLI for all metastatic sites as well as micro-CT for bone. Histological analysis will be performed to confirm the mammary carcinomas and metastases, and immunohistochemistry (IHC) of relevant cytokines (OSM and IL-6) will be performed to characterize the invasive tumor edge.

Statistical Analysis:

Statistical analysis will be performed with the assistance of our biostatistician, Laura Bond, MS, at Boise State University. In vitro experiments will be performed at least in triplicate with analysis by t-test and ANOVA with a priori multiple comparisons. Effects on organ specific and total metastatic burden, CTC numbers, tumor growth, and time to metastasis will be assessed by MANOVA. Conservative estimates from our preliminary data indicate that the proposed group size will give 80% power to detect differences in total metastatic burden of at least 20% at α=0.05. Greater power is anticipated for CTC numbers and tumor growth. The Kaplan-Meier test will be used to compare survival times between groups.

Example 11

1. Protein Oncostatin M Genbank

AAH11589 (SEQ ID NO: 1) MGVLLTQRTL LSLVLALLFP SMASMAAIGS CSKEYRVLLG QLQKQTDLMQ DTSRLLDPYI RIQGLDVPKL REHCRERPGA FPSEETLRGL GRRGFLQTLN ATLGCVLHRL ADLEQRLPKA QDLERSGLNI EDLEKLQMAR PNILGLRNNI YCMAQLLDNS DTAEPTKAGR GASQPPTPTP ASDAFQRKLE GCRFLHGYHR FMHSVGRVFS KWGESPNRSR RHSPHQALRK GVRRTRPSRK GKRLMTRGQL PR BC011589.1 (SEQ ID NO: 2) 1 gtcaccccca gcgggcgcgg gccggagcac gggcacccag catgggggta ctgctcacac 61 agaggacgct gctcagtctg gtccttgcac tcctgtttcc aagcatggcg agcatggcgg 121 ctataggcag ctgctcgaaa gagtaccgcg tgctccttgg ccagctccag aagcagacag 181 atctcatgca ggacaccagc agactcctgg acccctatat acgtatccaa ggcctggatg 241 ttcctaaact gagagagcac tgcagggagc gccccggggc cttccccagt gaggagaccc 301 tgagggggct gggcaggcgg ggcttcctgc agaccctcaa tgccacactg ggctgcgtcc 361 tgcacagact ggccgactta gagcagcgcc tccccaaggc ccaggatttg gagaggtctg 421 ggctgaacat cgaggacttg gagaagctgc agatggcgag gccgaacatc ctcgggctca 481 ggaacaacat ctactgcatg gcccagctgc tggacaactc agacacggct gagcccacga 541 aggctggccg gggggcctct cagccgccca cccccacccc tgcctcggat gcttttcagc 601 gcaagctgga gggctgcagg ttcctgcatg gctaccatcg cttcatgcac tcagtggggc 661 gggtcttcag caagtggggg gagagcccga accggagccg gagacacagc ccccaccagg 721 ccctgaggaa gggggtgcgc aggaccagac cctccaggaa aggcaagaga ctcatgacca 781 ggggacagct gccccggtag cctcgagagc accccttgcc ggtgaaggat gcggcaggtg 841 ctctgtggat gagaggaacc atcgcaggat gacagctccc gggtccccaa acctgttccc 901 ctctgctact agccactgag aagtgcactt taagaggtgg gagctgggca gacccctcta 961 cctcctccag gctgggagac agagtcaggc tgttgcgctc ccacctcagc cccaagttcc 1021 ccaggcccag tggggtggcc gggcgggcca cgcgggaccg actttccatt gattcagggg 1081 tctgatgaca caggctgact catggccggg ctgactgccc ccctgccttg ctccccgagg 1141 cctgccggtc cttccctctc atgacttgca gggccgttgc ccccagactt cctcctttcc 1201 gtgtttctga aggggaggtc acagcctgag ctggcctcct atgcctcatc atgtcccaaa 1261 ccagacacct ggatgtctgg gtgacctcac tttaggcagc tgtaacagcg gcagggtgtc 1321 ccaggagccc tgatccgggg gtccagggaa tggagctcag gtcccaggcc agccccgaag 1381 tcgccacgtg gcctggggca ggtcacttta cctctgtgga cctgttttct ctttgtgaag 1441 ctagggagtt agaggctgta caaggccccc actgcctgtc ggttgcttgg attccctgac 1501 gtaaggtgga tattaaaaat ctgtaaatca ggacaggtgg tgcaaatggc gctgggaggt 1561 gtacacggag gtctctgtaa aagcagaccc acctcccagc gccgggaagc ccgtcttggg 1621 tcctcgctgc tggctgctcc ccctggtggt ggatcctgga attttctcac gcaggagcca 1681 ttgctctcct agagggggtc tcagaaactg cgaggccagt tccttggagg gacatgacta 1741 atttatcgat ttttatcaat ttttatcagt tttatattta taagccttat ttatgatgta 1801 tatttaatgt taatattgtg caaacttata tttaaaactt gcctggtttc taaaaaaaaa 1861 aaaaaaaaa

Therefore, the present disclosure is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. The particular embodiments disclosed above are illustrative only, as the present invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular illustrative embodiments disclosed above may be altered, combined, or modified and all such variations are considered within the scope and spirit of the present invention. The invention illustratively disclosed herein suitably may be practiced in the absence of any element that is not specifically disclosed herein and/or any optional element disclosed herein. While compositions and methods are described in terms of “comprising,” “containing,” or “including” various components or steps, the compositions and methods can also “consist essentially of” or “consist of” the various components and steps. All numbers and ranges disclosed above may vary by some amount. Whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range is specifically disclosed. In particular, every range of values (of the form, “from about a to about b,” or, equivalently, “from approximately a to b,” or, equivalently, “from approximately a-b”) disclosed herein is to be understood to set forth every number and range encompassed within the broader range of values. Also, the terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee. Moreover, the indefinite articles “a” or “an,” as used in the claims, are defined herein to mean one or more than one of the element that it introduces. If there is any conflict in the usages of a word or term in this specification and one or more patent or other documents that may be incorporated herein by reference, the definitions that are consistent with this specification should be adopted. 

What is claimed:
 1. A kit of parts for use in inhibiting or reducing tumor cell detachment, proliferation and/or metastasis, comprising an OSM antagonist, and an administration vehicle, wherein said OSM antagonist is one or more of OSM-SMI-8, OSM-SMI-10, or OSM-SMI-11.
 2. A pharmaceutical composition comprising a unit dose of at least 1 mg of an antagonist to oncostatin M (OSM), and a pharmaceutically acceptable carrier, wherein said OSM antagonist is one or more of OSM-SMI-8, OSM-SMI-10, or OSM-SMI-11.
 3. The pharmaceutical composition according to claim 2 wherein the antagonist is combined with a chemotherapy agent.
 4. The pharmaceutical composition of claim 2, wherein said composition is effective for inhibiting or reducing the spread of a primary tumor to a pre-metastatic organ of the subject.
 5. The pharmaceutical composition of claim 2, wherein the antagonist is combined with an effective amount of gp-130 antagonist.
 6. A pharmaceutical composition for use in inhibiting or reducing tumor cell detachment, proliferation and/or metastasis, comprising an effective amount of an antagonist to OSM, wherein the OSM antagonist is one or more of OSM-SMI-8, OSM-SMI-10, or OSM-SMI-11 and a pharmaceutically acceptable carrier.
 7. The pharmaceutical composition of claim 5, wherein the OSM antagonist is combined with a chemotherapy agent, an immune modulator or an anti-OSM antibody or a fragment thereof.
 8. The pharmaceutical composition of claim 6, wherein reducing tumor cell detachment, proliferation and/or metastasis comprises reducing size or number of lung metastases. 